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1. Introduction
1.1 The Immune System
The  main  purpose  of  the  immune  system is  to  protect  the  integrity  of  its  host  by
identifying and eliminating pathogens.
It can be subdivided into the less specialized but immediately reacting innate and the
highly specialized but slower-reacting adaptive immune system.
1.1.1 The Innate Immune System
There are different components of the innate immune system. The first line of defence
consists of barriers, such as the skin, acidic body fluids or excretion mechanisms. The
commensal microbial flora can also be considered part of this. For pathogens which
circumvent or withstand these barriers, cells of the innate immune system spring into
action, consisting mainly of phagocytes but also a much smaller fraction of natural killer
cells (NK).
This  second  line  of  defence  is  able  to  identify  foreign  molecules  called
pathogen-associated  molecular  patterns  (PAMPs)  like  fungal  mannans  or  bacterial
lipopolysaccharide  (LPS)  via  pattern  recognition  receptors  (PRRs)  such  as  toll-like
receptors (TLRs), humoral identification or a combination of both (1).
Innate  humoral  immunity operates  in  three main ways:  the complement  system, the
acute phase proteins and pro-inflammatory cytokines that the cells of the innate immune
system (especially  macrophages)  secrete.  The  complement  system consists  of  many
different proteins circulating in the blood stream. It has the ability to opsonize (mark for
phagocytosis) or lyse pathogens directly, depending on the activated cascade.
Pro-inflammatory  cytokines  like  TNF,  IL-1  and  IL-6  can  cause  fever,  attract  more
immune cells and stimulate the production of acute-phase proteins like the C-reactive
protein  (CRP),  which  in  turn  acts  as  an  opsonin  and  helps  to  activate  the  lytic
complement cascade (2). 
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1.1.2 The Adaptive Immune System
Like the innate immune system, the adaptive immune system also has a cellular and a
humoral  component,  both  of  which  are  essentially  represented  by  two  types  of
lymphocytes with very distinct roles.
The  B lymphocytes  (B cells),  which  can  transform into  antibody-producing plasma
cells,  represent  the  backbone  of  the  humoral  component,  and  the  many  subsets  of
T lymphocytes (T cells) make up the cellular component. Both types are created in the
bone marrow, but only B cells remain there for maturation, while T cells emigrate to the
thymus. In the thymus, T cells undergo processes of positive and negative selection to
ensure that they recognize major histocompatibility complex (MHC) molecules with
their T cell receptor and that their affinity to self-antigens is sufficiently low.
1.1.3 Antigen-Presenting Cells
The adaptive  immune system can reach its  full  potential  by  being provided with  a
specific  target.  Specialized  antigen-presenting  cells  (APC)  are  cells  capable  of
incorporating and processing antigens (e. g. pathogens or their fragments) which are
then presented on the cell surface via the MHC II protein. Among the specialized APC
are  B  cells,  macrophages  and  dendritic  cells  (DC).  Other  cells  can  only  present
endogenous  antigens  (e.  g.  viral  peptides)  via  MHC  I  after  degradation  in  the
proteasome. Proteasomes  are  intracellular  protein-structures  which  degrade  old  or
damaged proteins, as well as endogenous antigens.
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Figure 1.1.3: Modified from “The Antigen-presentation Pathways in DC”  (3)  
Intracellular antigens are degraded via the proteasome, then transported into the endoplasmatic reticulum where
they are loaded onto MHC I proteins. This antigen-loaded MHC I is then sent to the cell membrane to be presented
on the cell surface.
Extracellular  antigens  are  incorporated  into  the  cell  via  endocytosis,  then  degraded  and  loaded  onto  MHC II
proteins in the endosome. The antigen-loaded MHC II is then sent to the cell membrane to be presented on the cell
surface. Some intracellular proteins are also presented via MHC II. 
DC can cross-present extracellular antigens via MHC I. The exact mechanism of this pathway is as of yet unknown.
TAP – transporter associated with antigen processing
Their  inhibition causes intracellular protein accumulation and changes to the cellular
peptidome (4). DC have the unique ability to present exogenous antigens on both MHC
molecules. This is called cross-presentation (5, 6).
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1.1.4 T Cell Subsets
Surface  molecules  are  crucial  for  differentiating  cell  subsets.  Virtually  all  T  cells
express the CD3 molecule and the T cell receptor (TCR), but they can be divided into
T cells that express CD4, CD8 or neither of the two. 
CD4+ T cells include helper T cells (Th) and regulatory T cells (Treg). Both classes and
their respective subclasses are differentiations of the naive CD4+ T cell.
Th cells  have several  subsets  and promote  immunity  with  their  cytokines  but  every
subset also needs a distinct combination of cytokines for their differentiation from the
naive  CD4+ cell.  Th1 cells  need  IL-12  and  IFN-γ  and  have  the  ability  to  promote
inflammation  and  cellular  immunity.  They  do  so  by  activating  macrophages  and
cytotoxic  CD8+ T  cells  while  suppressing  Th2 immunity  (7).  On  the  other  hand,
Th2 cytokines  support  humoral  immunity  by  stimulating  antibody  production  and
immunoglobulin class switching in B cells.
Treg cells generate immune tolerance by secreting IL-10 and TGF-β as anti-inflammatory
cytokines but also need TGF-β along with IL-2 for their formation. 
There are also cell contact dependent mechanisms of interaction between T cells and
other immune cells, the two most notable examples being the interaction with APC and
the interaction with B cells. 
To become a Th cell, the CD4+ T cell engages the MHC II presented antigen with its
TCR. However,  the result  of this  alone would be an anergic T cell.  The interaction
between CD28 on the T cell and the appropriate ligands CD80 and CD86 on the APC
surface provides the necessary costimulation (8) (see also figure 1.1.5).
B  cells  can  recognize,  incorporate  and  degrade  circulating  antigens  as  well.  The
presented antigen on the cell  surface is  then recognized by  T follicular  helper  cells
(Tf h cells) with an antigen-specific TCR. Upon recognition, the Tf h cells express CD40
ligand (CD40L) and secrete IL-21. CD40L binds to the receptor molecule CD40 on
B cells and is the requisite co-stimulus for B cell proliferation and differentiation into
plasma  cells  and  also  memory  B  cells,  which  can  be  activated  more  quickly,  so
re-infections with the same pathogen can be fought more efficiently; IL-4 and IL-21
9
support this effect (9, 10).
CD8+ cells can recognize proteins presented via MHC I on every cell of the organism.
When an aberrant cell, virus-infected or neoplastic, expresses proteins that differ from
the norm, the CD8+ cell can transform into the cytotoxic T lymphocyte (CTL). This
effector cell can secrete IFN-γ along with perforins and granzymes as cytolytic agents to
induce apoptosis of the aberrant cell. Additionally, T cells have the ability to engage the
CD95  surface  molecule  with  the  CD95  ligand  which  induces  programmed  cell
death (11). After eliminating the threat, homeostasis has to be restored: plasma levels of
certain humoral agents and cell counts have to decline. Effector cells go into apoptosis
via CD95 ligand binding (12) while memory cells remain in circulation.
1.1.5 Dendritic Cells
Dendritic  cells  (DC)  are  specialized  APC  which  can  be  found  in  many  tissues,
especially  those  that  act  as  a  barrier  against  pathogens.  An  example  would  be  the
Langerhans cells residing mostly in the skin and mucosal tissue. DC were first described
as such by Steinman and Cohn in 1973, but their  high potential  and pivotal  role in
adaptive  immunity  was  discovered  within  the  following  25  years  by  Steinman  and
Banchereau (13, 14).
DC originate from CD34+ progenitor cells in the bone marrow, enter the bloodstream as
precursors  and  have  the  task  of  scanning  their  environment  in  different  tissues  for
pathogens. They are then called immature DC (iDC), which excel at antigen recognition
via PRRs and endocytosis. Having been activated by an antigen or PAMP, iDC migrate
to secondary lymphoid organs while processing the antigen. Migration is possible due to
an up-regulation of the C-C chemokine receptor type 7 (CCR7), which guides DC to the
lymph nodes. During migration, they lose their high potential for antigen recognition
and endocytosis while profoundly improving their aptitude for antigen-presentation and
co-stimulation. After completing this process they are now called mature DC (mDC).
Their main function is to present the processed antigen via MHC and thereby select an
appropriate T cell clone for clonal expansion. Once a suitable T cell makes contact with
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the  MHC  presented  antigen  via  its  TCR,  the  mDC  can  supply  the  necessary
costimulatory surface molecules – especially CD80 and CD86, but also CD83 (15) – as
well as supporting cytokines (e. g. IL-12). DC can also be activated by T cells binding
to CD40L. This leads to increased expression of costimulatory molecules, secretion of
more cytokines and indirectly supports B cell organization (16). Their high potency as
APCs results in DC being able to directly prime naive T cells to specific antigens and
therefore link innate to adaptive immunity (17).
While mDC can promote immunity, iDC can have the opposite effect, creating immune
tolerance. Steinman showed this effect by targeting DC without a maturation adjuvant to
suppress type I diabetes in mice (18). 
One can differentiate between myeloid and plasmacytoid DC. Myeloid DC have many
subsets like the aforementioned Langerhans cells. Plasmacytoid DC look like plasma
cells  while also having TLRs for antigen recognition.  After stimulation they secrete
large amounts IFN-α and IFN-β (19).
A special subset of DC are the monocyte-derived DC (MoDC). They can be generated
in  vitro by subjecting  CD14+ monocytes  to  the  cytokines  IL-4  and  GM-CSF.  Their
maturation can be induced via different stimuli like TNF or LPS.
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Figure 1.1.5: Modified from “  Outline of normal DC differentiation and the role of DC in antitumour immunity”  (20)  
DC originate from hematopoietic progenitor cells (HPC) cells in the bone marrow, enter the bloodstream (with the
intermediate form between the two being the common myeloid progenitor – CMP – which can differentiate into all of
the non-lymphoid blood cells) as immature myeloid cells (iMC), then differentiate and migrate towards peripheral
tissues where they monitor the environment for antigens (in this example tumour antigen) as iDC. Upon antigen
uptake the process of maturation begins.  Migratory capacity increases (exemplified by CCR7) and the DC start
degrading and presenting the antigen via MHC during migration towards the draining lymph node. They lose their
high  potential  for  antigen  recognition  and  endocytosis  while  profoundly  improving  their  aptitude  for  antigen-
presentation and co-stimulation. In the lymph node, once a suitable T cell makes contact with the MHC presented
antigen via its TCR (signal 1), the mDC can supply the necessary costimulatory surface molecules CD80 and CD86
(signal 2) as well as supporting cytokines (e. g. IL-12). Because of their ability to cross-present they can activate both
CD4+ and  CD8+ T cells.  The CD4+  T cells  can  then provide  additional  cytokines to  help specific  CD8+ clonal
expansion (or facilitate humoral immunity via Th2 differentiation). The CD8+ effector cells then go on to eliminating
the  structure  they  have  been  primed  against  (tumour  cells  in  this  example).  TCR  –  T-cell  receptor;
TNF –  tumour-necrosis factor
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1.1.6 Carcinogenesis
Tumour cells have disassociated their growth and proliferation from the external stimuli
that tightly regulate normal cell cycles. Internal apoptotic stimuli like DNA damage and
the  p53  tumour  suppressor  gene  are  rendered  ineffective,  proliferation  factors  are
amplified. Angiogenesis (in solid tumours) is promoted and restrictions on the number
of mitotic cycles are lifted. 
The aforementioned features are found in cancer as well as benign tumours to some
extent;  a  feature  largely  exclusive  to  malignant  neoplasms  is  tissue  invasion  and
metastasis. All of these attributes have been characterized by Hanahan and Weinberg in
2000 (21). They revisited their article in 2011 and added four new characteristics to the
previously mentioned six: an unstable genome with resulting mutation, a metabolism
which is skewed to favour glycolysis over mitochondria dependent energy generation,
tumour-promoting inflammatory processes mediated by invading cells of the immune
system and immune escape (22). Immune escape is the ability of tumour cells to evade
immune surveillance. It is comprised of several distinct interactions between tumour
cells  and certain  branches  of  the  immune system. Recruitment  of  Treg cells  towards
tumour  sites,  modulation  of  myeloid  cells,  down-regulation  of  tumour  antigen
expression via MHC I and the ability to induce T cell anergy via TCR binding without
co-stimulation  contribute  to  this  as  well  as  secretion  of  cytokines  like  IL-10
and TGF-β (23).
The  iDC  subjected  to  increased  levels  of  these  cytokines  cannot  develop  the  co-
stimulatory capacity of mDC which results in tumour-specific immune tolerance  (20).
The Th cell formation is also skewed towards Th2 by these cytokines which decreases the
efficacy of a CTL response (24).
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1.1.7 Cancer Immunotherapy and DC Vaccination
In recent years there have been different approaches to manipulate the immune system
into  acting  against  cancer  cells:  monoclonal  antibodies  (e.g.  trastuzumab  for  breast
cancer treatment) have become a staple in oncology; cytokines like interferons and IL-2
are also used in certain protocols.
Because of their ability to prime naive T cells to a specific antigen, DC are targeted by
available vaccines against microbial antigens. They can also be used to vaccinate cancer
patients against their tumour. A major advantage of this is that it is a systemic therapy
with few side effects which is important because many of the mostly old patients are in
poor general health, making them unable to endure harsh chemotherapy regimens. Other
advantages over conventional chemotherapy are being independent of the tumour cell
cycle (especially in slow-growing tumours) and the possible usage against tumours or
metastases of privileged organs like the brain where only few chemotherapy drugs can
reach.  In  these  therapeutic  vaccinations,  the  induction  of  tumour-specific  T cells  is
critically important for their efficacy and is therefore the main goal of tumour vaccines
(see figure 1.1.7 a).
There are several ways to develop and administer tumour vaccines, but DC involvement
is vital (25).
Vaccine  formulations  can  be based on peptides,  proteins,  DNA, mRNA, bacteria  or
viruses,  heat shock proteins,  antibodies and tumour cells. In the past a multitude of
cancer vaccines have been tested, but despite achieving long-lasting remissions in some
patients  most  of  them  did  not  meet  expectations  in  terms  of  clinical  response,  as
published by Filipazzi et al. and Leffers et al. for peptide-based vaccines in melanoma
and ovarian cancer patients,  respectively  (26, 27).  However,  some success has been
achieved treating metastatic renal cell carcinoma with a combination of a multipeptide
vaccine, GM-CSF and the immunosuppressant cyclophosphamide. GM-CSF served as a
DC immunostimulant while a cyclophosphamide single-dose 3 days prior to vaccination
reduced the number and activity of Treg cells  (28). As of now, it is unclear why some
vaccines are effective as opposed to others.
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Figure 1.1.7 a: Modified from
“Manipulating  the  immune
response to tumours.  ”  (29)   
The goal  of  tumour vaccines
is  to  induce  a  tumor-specific
T cell  response  where  none
existed before and to amplify
or  diversify  an  already
existing one.
Being  able  to  create  individualized  vaccines  is  an  advantageous  property  of  this
therapeutic  approach.  This  was  already  tried  on  patients  with  minimal  disease
lymphoma  or  in  remission  after  chemotherapy  by  Kwak  et  al. in  1992  and  they
succeeded  in  eliciting  an  immune  response  to  the  vaccine  in  patients  (30).
Patient-specific  antigens  were tested  in  a  vaccine  in  combination  with  GM-CSF on
follicular lymphoma patients which led to a significant clinical benefit  (31). Finding
suitable  tumour  antigens  for  vaccination  is  important.  Tumour-associated  antigens
(TAA)  and  tumour-specific  antigens  (TSA)  are  the  usually  the  main  subgroups
classified. TAA can be regularly occurring antigens which are simply up-regulated on
tumour cells (e. g. HER2 and PSA) and TSA can be viral gene products (e. g. stemming
from the  human  papilloma virus)  or  products  of  mutated  genes  (neoantigens)  (29).
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Neoantigens  are  especially  interesting  because  some  of  the  corresponding  T cell
responses have been shown to be associated with tumor regression or long-term disease
stability (32, 33). 
Adjuvants  are  important  additional  components  many  vaccines.  They  augment  and
potentially modify the immunological effect of vaccines. Immune reactions to peptides
are mostly very limited so adding at least one adjuvant is imperative for their efficacy as
a vaccine. Empirically derived adjuvants and natural or synthetic ligands of different
TLR subtypes can be considered for this purpose (34, 35). 
Ex vivo generated DC can also be used in therapeutic cancer vaccines. They can be
generated either by exposing CD34+ progenitor cells to GM-CSF and FLT3 ligand or
monocytes with GM-CSF and IL-4. They are then subjected to the desired antigen after
which they may be activated with TNF or TNF and CD40L (see figure 1.1.7 b).
Figure 1.1.7 b: Modified from “The state of the art in translating DC vaccines to the clinic”  (36)  
This figure shows how a DC vaccine is generated: Patient white blood cells are extracted via leukapheresis and the
desired cell type is subsequently separated from the rest and cultivated with suitable cytokines for differentiation into
iDC. These cells can then be loaded with different types of antigen as shown. The DC are then provided with a
maturation stimulus and prepared for introduction into the patient’s system.
These DC have been tested with some success on multiple myeloma patients (37, 38),
especially when introduced after an autologous stem cell transplant (39, 40), as well as
stage IV melanoma patients (41). Furthermore, a vaccination protocol with this type of
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DC  has  been  established  and  approved  by  the  FDA metastatic  castration-resistant
prostate cancer after a successful phase 3 trial showed that it prolonged overall patient
survival (42). Immune tolerance can also be induced by specific targeting. This has been
shown in vitro for human DC and in vivo for non-human primates (43). 
1.2 Multiple Myeloma
Multiple myeloma belongs to the group of non-Hodgkin-lymphoma, more accurately to
the subgroup of mature B cell lymphoma. The malignant cell is a plasma cell clone,
which  often  produces  abnormal  antibodies  called  paraproteins.  These  can  belong to
every immunoglobulin (Ig) subclass. IgG and IgA are the most common, while IgD and
IgE types are rare. Another subclass is the light chain myeloma in which the plasma cell
clone secretes κ- or λ light chain parts instead of complete antibodies. The most relevant
specific  risk  factor  for  multiple  myeloma  is  the  monoclonal  gammopathy  of
undetermined  significance  (MGUS),  which  is  defined  by  the  amount  of  circulating
paraprotein, the amount of plasma cells in the bone marrow and the lack of myeloma
symptoms  in  terms  of  damage  or  unregulated  B  lymphocyte  proliferation.  The
prevalence  of  MGUS  is  fairly  high  in  the  elderly,  and  while  most  of  them  never
transform, a large majority of patients have had MGUS prior to multiple myeloma (44).
The risk of transformation increases by 1-2 % per year, but since it is primarily a disease
of old age, many of the people with MGUS die of some other cause before progressing.
Multiple myeloma is distinguished from MGUS by 3 main criteria: more than 10 %
bone  marrow  plasma  cells,  monoclonal  immunoglobulin  in  serum  protein
electrophoresis or urine (Bence Jones protein) and myeloma associated organ damage
(elevated blood calcium, renal failure, anemia, compromised bone stability).
A patient’s prognosis used to be evaluated with the Durie and Salmon staging criteria
which  were  an  attempt  at  objectifying  the  associated  organ  damage.  The  current
approach with the Revised International Staging System (R-ISS) only takes into account
β2-microglobulin  (tumour  marker),  albumin,  cytogenetic  risk  group  and  LDH  (45).
Multiple myeloma cases amount to almost 20 % of hematological and 1.6 % of all
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cancers (46); the age adjusted incidence is 6.6/100,000 based on United States data from
2010  to  2014  (47).  There  are  many  chemotherapy  regimens  for  inducing  and
maintaining remission of  multiple  myeloma.  Patients  who are  physically  strong can
receive high-dose chemotherapy with subsequent autologous stem cell transplantation.
This does not cure the disease but allows for more chemotherapy to be administered and
can  thus  prolong  remission  and  survival  (48).  Advancements  in  terms  of
immunomodulatory  drugs  including  thalidomide,  lenalidomide  and  especially
proteasome  inhibitors  have  improved  therapeutic  options  considerably  (see  chapter
1.2.1), but multiple myeloma still remains mostly incurable with 5-year survival rates of
less than 50 % (47). In addition to that, other age-related diseases prevent eligibility for
stem cell treatment. Therefore, new treatment approaches are desirable. Avenues that
have  been  explored  include  specific  antibody-chemotherapy  conjugates,  specific
immunomodulatory  antibodies,  proteasome  inhibitors  and  also  anti-tumour  vaccines
(37, 38, 49).
1.2.1 Proteasome Inhibition as a Therapeutic Principle
In 2008 the FDA granted bortezomib their approval for the initial treatment of multiple
myeloma in the USA because its addition to the standard treatment prolonged median
patient survival by 5 months in comparison to the standard of melphalan and prednisone
(50). Bortezomib inhibits the 26S proteasome with its boron atom (51). The anti-tumour
effect of proteasome inhibition suggests that multiple myeloma cells and some other
tumours  rely  on  proper  proteasome  function.  The  most  common  side  effects  are
peripheral neuropathy and neuralgia, thrombocytopenia, asthenic conditions, diarrhea,
constipation,  immunosuppression  and  anemia.  Subcutaneous  instead  of  intravenous
administration  seems  to  reduce  the  occurrence  of  side  effects,  especially  peripheral
neuropathy  (52). Clinical response rates are high and can be further improved when
combined with dexamethasone in untreated myeloma (53). The response rate in relapsed
myeloma is also quite high in combination with cyclophosphamide and dexamethasone
(54). 
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In  2012  the  United  States  FDA granted  carfilzomib  (trade  name:  Kyprolis®)  their
approval  for  the treatment  of relapsed multiple  myeloma after  failed treatment  with
bortezomib and immunomodulatory drugs (55, 56). This second-generation proteasome
inhibitor  is  derived  from  epoxomicin,  which  is  a  naturally  occuring  proteasome
inhibitor isolated from an Actinomycetes strain.. Instead of inhibiting the proteasome
competitively like bortezomib, it inhibits the 20S proteasome by irreversibly binding to
it  (57), which leads to an accumulation of proteins that are conjugated with ubiquitin
and thus marked for degradation  (58). Adverse side effects include thromobcytopenia,
anemia,  cardiac  toxicity,  renal  impairment,  dyspnea,  hepatotoxicity  and  peripheral
neuropathy. Cardiac toxicity seems to be more common under carfilzomib treatment
when compared to  bortezomib while  bortezomib causes  peripheral  neuropathy more
often (59).
The ensuing ASPIRE and ENDEAVOR studies have shown high response rates and
improved  progression  free  survival  in  combination  with  lenalidomide  and
dexamethasone  when  compared  to  the  control  without  carfilzomib  for  relapsed
myeloma  (60) and  have  shown comparable  results  with  only  dexamethasone  when
compared to bortezomib with dexamethasone in relapsed or refractory myeloma (61).
1.3 Effects of Proteasome Inhibition on DC – Project Objective
Disregarding allogeneic stem cell transplantation because of high mortality rates  (62),
multiple  myeloma  remains mostly  incurable.  In  a  practical  sense,  however,  a  long
lasting disease remission with low treatment-related side effects can be a worthwhile
substitute for a cure. DC based vaccination combined with well tolerated anti-myeloma
substances like carfilzomib could be a possible model for this treatment approach. There
are  at  the  very  least  two  prerequisites  that  are  paramount  for  this  to  be  viable:
1. Proteasome inhibition can modulate MHC I dependent antigen presentation  (63). If
this effect nullified the expression of suitable antigens for targeting on myeloma cells,
the success of the aforementioned combined approach would be unlikely. 2. DC have to
retain proper function during a treatment regimen that includes carfilzomib. 
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Previous studies of our working group have shown that bortezomib adversely affects
MoDC viability and function in several ways including skewed phenotypic maturation,
less  migratory  and  stimulatory  capacity,  as  well  as  less  secretion  of  inflammatory
cytokines and less endocytic capacity (64, 65). Due to its adverse effects on the function
of MoDC, bortezomib does not seem to be a suitable candidate for a combined approach
with  vaccination  therapy.  As  carfilzomib  inhibits  the  proteasome  via  a  different
mechanism  than  its  predecessor  bortezomib,  the  effect  might  be  different,  less
pronounced or even non-existent, which would be most desirable in combination with
vaccines. It has been demonstrated that myeloma cells have the ability to evade CD8+
T cells  by  interacting  with  the  immune  system  and  subsequently  down-regulating
surface  antigens  (66).  That  is  why  the  recent  identification  of  potential  targets  for
vaccination by Walz  et al. was important. They found 58 highly specific peptides in
myeloma cell lines which seemed to elicit a pertinent CD8+ T cell response in myeloma
patients (67). Shortly thereafter, Kowalewski et al. showed that some of those specific
peptides  on  the  MM.1S  and  the  U266  cell  lines  were  stably  expressed  or  even
temporarily up-regulated under carfilzomib treatment  (68). Sufficient immunogenicity
provided, vaccines based on these peptides could improve patient outcome. 
In  this  study  we  aimed  to  demonstrate  the  effect  of  carfilzomib  on  human  MoDC
function compared to the effect of bortezomib in order to assess its suitability for a
two-pronged approach with DC vaccination therapy.
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2. Materials
2.1 Devices
Table 2.1: Devices
Device Manufacturer
Flow cytometer: FACSCalibur BD Biosciences, Heidelberg, Germany
Optical microscope: Axiovert 25 CFL Carl Zeiss AG, Oberkochen, Germany
Sunrise Absorbance Microplate Reader Tecan Trading AG, Männedorf Switzerland
Pipetboy INTEGRA  Biosciences  GmbH,  Biebertal,
Germany
APT.line C150 (E2) CO2 Incubator BINDER, Tuttlingen GmbH, Germany
Laminar flow cabinet Heraeus Instruments, Hanau, Germany
Kendro Laboratory Products, Langenselbold,
Germany 
Laboratory  vacuum  pump:  VACUSAFE
comfort
INTEGRA  Biosciences  AG,  Zizers,
Switzerland 
Reagenzglasschüttler TYP Reax I Heidolph Instruments, Schwabach, Germany 
MS2 Minishaker IKA Works, Wilmington, NC, USA
Shaking water bath: No 1083 GFL Gesellschaft  für  Labortechnik  GmbH,
Burgwedel, Germany
Freezer -80 °C, Model 8963 Thermo  Fisher  Scientific,  Waltham,  MA,
USA
Freezer -80 °C, Ultra Low Temperature 
Freezer UF V 500
BINDER, Tuttlingen GmbH, Germany
Dynatech MR7000 ELISA plate reader Dynatech Laboratories, Chantilly, USA
Freezer -20 °C Liebherr, Biberach and der Riss, Germany
Refrigerator 4 °C Liebherr, Biberach and der Riss, Germany
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Mr. Frosty freezing container Thermo  Fisher  Scientific,  Waltham,  MA,
USA
Pipettes  10 µl,  100 µl,  200 µl,  1000 µl,
Handystep repetitive pipette 
Eppendorf, Hamburg, Germany
Brand, Wertheim, Germany
Centrifuges
Thermo IEC Centra-GP8R ThermoQuest, Engelsbach, Germany
Centrifuge 5804 R Eppendorf AG, Hamburg, Germany
Heraeus Fresco 17 Centrifuge Thermo  Fisher  Scientific,  Waltham,  MA,
USA
Biofuge fresco Kendro  Laboratory  Products,  Osterode,
Germany
Megafuge 1.0 R Kendro  Laboratory  Products,  Osterode,
Germany
2.2 Expendable Materials
Table 2.2: Expendable Materials
Product Manufacturer
SurPhob SafeSeal LOW BINDING filtered
tips sterile 10 µl, 100 µl, 1000 µl 
Biozym  Scientific,  Hessisch  Olendorf,
Germany
Combitips plus 2.5 ml Eppendorf AG, Hamburg, Germany
Multitips 5 ml Ritter medical, Schwabmünchen, Germany
Pasteur pipettes, sterile Roth, Karlsruhe, Germany
5 ml polystyrene round-bottom tube BD Biosciences, Heidelberg
Eppendorf Safe-Lock Tubes, 1.5 ml Eppendorf AG, Hamburg, Germany
Tissue culture flask 25 cm2, 75 cm2 Corning Falcon, Corning, NY, USA 
Conical Centrifuge Tubes, 50 ml Corning Falcon, Corning, NY, USA 
Conical Centrifuge Tubes, 15 ml Merck KGaA, Darmstadt, Germany
22
Nunc CryoTubes,  conical  bottom,  starfoot,
free standing, 1,0 ml, 1,8 ml
Merck KGaA, Darmstadt, Germany
Falcon  Tissue  culture  plate,  6  well,  flat
bottom
Becton Dickinson and Co., Franklin Lakes,
NJ, USA
Cellstar  Cell  culture  plate,  96  well,  flat
bottom, U-bottom
Merck KGaA, Darmstadt, Germany
Falcon  Cell  Culture  Inserts,  6.4 mm,
8.0 µm pores
Corning Falcon, Corning, NY, USA
Falcon  Tissue  culture  plate,  24  well,  flat
bottom
Corning Falcon, Corning, NY, USA 
2.3 Agents
2.3.1 Buffers, Solutions, Chemicals
Table 2.3.1: Buffers, Solutions, Chemicals
Product Manufacturer
Dulbecco's  Phosphate  Buffered  Saline,
Without CaCl2 and MgCl2 (PBS) 500 ml
SIGMA-ALDRICH, St. Louis, MO, USA
MACS BSA stock solution Miltenyibiotec,  Bergisch  Gladbach,
Germany
FACS buffer PBS+25 ml MACS BSA stock solution
Biocoll separating solution Biochrom AG, Berlin, Germany
Trypan blue Thermo  Fisher  Scientific,  Waltham,  MA,
USA
Formalin solution neutral buffered 10 % SIGMA-ALDRICH, St. Louis, MO, USA
Staurosporine R&D Systems, Wiesbaden, Germany
Carfilzomib SelleckChem, Munich, Germany
Kyprolis® (carfilzomib) Amgen Europe GmbH, Zug, Switzerland
Velcade® (bortezomib) Millennium Pharmaceuticals (Takeda), 
Cambridge, MA, USA 
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2.3.2 Media and Additives
Table 2.3.2: Media and Additives
Product Manufacturer
Gibco RPMI 1640 Medium Thermo  Fisher  Scientific,  Waltham,  MA,
USA
X-vivo 20 Lonza, Basel, Switzerland
Fetal calf serum (FCS) Merck KGaA, Darmstadt, Germany
FcR Blocking Reagent Miltenyibiotec,  Bergisch  Gladbach,
Germany
Freezing medium FCS + 10 % DMSO
Antibiotics: penicillin/streptomycin Thermo  Fisher  Scientific,  Waltham,  MA,
USA
2.3.3 Fluorescent Antibodies for Flow Cytometry
Table 2.3.3: Fluorescent Antibodies for Flow Cytometry
Product Manufacturer
FITC Mouse IgG1 BD Biociences, San Jose, CA, USA
FITC Mouse Anti Human CD1a BD Biociences, San Jose, CA, USA
FITC Anti Human CD80 eBioscience, San Diego, CA, USA
FITC Mouse Anti-Human CD209 BD Biociences, San Jose, CA, USA
PE Mouse IgG 1 x Iso Control eBioscience, San Diego, CA, USA
PE Anti-Human CD83 eBioscience, San Diego, CA, USA
PE Anti-hCCR7 R&D Systems, Minneapolis, MN, USA
Human Osteoactivin Antibody (conjugated 
with PE in-house)
R&D Systems, Minneapolis, MN, USA
PE Anti-hDC-SIGN R&D Systems, Minneapolis, MN, USA
PerCP IgG 2B Isotype Control R&D Systems, Minneapolis, MN, USA
PerCP Anti-CD14 BD Biociences, San Jose, CA, USA
PerCP Anti-hDC-SIGN R&D Systems, Minneapolis, MN, USA
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APC IgG Isotype Control R&D Systems, Minneapolis, MN, USA
APC Anti-Human HLA-DR eBioscience, San Diego, CA, USA
APC Mouse Anti-Human CD86 BD Biociences, San Jose, CA, USA
APC Mouse Anti-Human CD209 BD Biociences, San Jose, CA, USA
2.3.4 Cytokines
Table 2.3.4: Cytokines
Product Manufacturer
Leukine (Sargramostim/GM-CSF) Sanofi-Aventis, Bridgewater, NJ, USA
IL-4 R&D Systems, Wiesbaden, Germany
IL-10 R&D Systems, Wiesbaden, Germany
CCL19/MIP-3β R&D Systems, Wiesbaden, Germany
2.4 Miscellaneous
Table 2.4: Miscellaneous
Product Manufacturer
ELISA kit: MIP-1α/CCL3 R&D Systems, Wiesbaden, Germany
ELISA kit: RANTES/CCL5 R&D Systems, Wiesbaden, Germany
ELISA kit: IL-6 BD Biociences, San Jose, CA, USA
ELISA kit: IL-12 BD Biociences, San Jose, CA, USA
ELISA kit: MCP-1/CCL2 R&D Systems, Wiesbaden, Germany
Annexin-V-Fluos Staining Kit Roche  Diagnostics  GmbH,  Mannheim,
Germany
Myeloma cell line: U266 Leibniz Institute DSMZ - German Collection 
of Microorganisms and Cell Cultures GmbH, 
Braunschweig, Germany
Statistics Software SAS JMP 13 Windows SAS Institute Inc., Cary, NC, USA
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3. Methods
3.1 Generation of Human MoDC
Processing the primary material (buffy coats) to attain MoDC monocultures which are
pure  enough to use  them in  subsequent  tests  takes  approximately  one  week.  In the
following paragraphs this process will be described in further detail.
3.1.1 Isolating Peripheral Blood Mononuclear Cells
Completely anonymised buffy coats1 were obtained from blood donations to the blood
bank Tübingen for isolating peripheral blood mononuclear cells (PBMC). It was done
by diluting the buffy coat at a 1:4 ratio with phosphate buffered saline (PBS) and then
layering it over a cell separating solution (Biocoll seperating solution). This polymer
solution has a molecular weight of 400,000 Dalton and a density of 1.077 g/ml. 30 ml of
diluted buffy coat were layered over 12 ml of cell separating solution. After 20 minutes
of centrifugation at 806·g and room temperature, there were four visible layers in order
from  top  to  bottom  of  the  tube:  plasma  layer,  layer  of  mononuclear  cells  and
thrombocytes,  separating  solution,  layer  of  non-mononuclear  cells.  The layer  of  the
mononuclear cells was then removed with a pasteur pipette and transferred to 2 unused
tubes.
To remove any remnants of the separating solution, these cells were then rinsed twice
by adding approximately 45 ml of PBS and removing the supernatant after 5 minutes in
the centrifuge at 453·g. To remove a portion of the thrombocytes, the cells were then
rinsed a third time at 250·g after adding 25 ml of PBS. The cells were then combined in
one tube and counted. After another 5 minutes in the centrifuge, the cells were dispersed
in X-Vivo 20 cell medium and distributed evenly across several cell culture flasks for
adhesion of the peripheral blood monocytes (69).
1 The use of anonymised buffy coats has been approved by the ethics board of the University. No 
personal data of any donor was received or used in this study.
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3.1.2 Counting Live PBMC in the Neubauer Chamber
The PBMC pellet was dispersed in 40 ml of PBS. 10 µl of the cell suspension, and 10 µl
of Trypan blue were diluted with 80 µl of PBS, so a 1:10 dilution was achieved. 10 µl of
blue dyed diluted cell  suspension were then transferred into the Neubauer  chamber.
Cells were counted in diagonally opposite fields of 16 squares each. The cell count in 40
ml of cell suspension was calculated as follows:
Cellcount · 0.5 · 40 · 10 · 104
The factor 0.5 is used for creating the mean count from both fields counted, 40 is the
total volume of cell suspension in ml, 10 is the dilution factor of the cell suspension in
the Neubauer chamber relative to the 40 ml of cell suspension and 104 is the constant
factor of the Neubauer chamber.
3.1.3 Starting MoDC Cultures
MoDC cultures were started using 75 cm2 cell culture flasks with no more than 12·107
and no less than 6·107 peripheral blood mononuclear cells (PBMC) in 10 ml of cell
culture fluid.  Cell  cultures with low yields of PBMC were started using 25cm2 cell
culture flasks with no more than 5·107 and no less than 3·107 PBMC in 5 ml of cell
culture fluid.
After no less than 90 minutes and no more than 120 minutes of adhesion time at 37 °C
and  5  % CO2,  the  non-adherent  cells  were  rinsed  off  with  the  X-Vivo  20  in  their
respective flask and room temperature PBS; the X-Vivo 20 was replaced by RPMI cell
culture medium with bovine fetal calf serum and penicillin/streptomycin as additives
(69). IL-4 (20 ng/ml cell suspension) and GM-CSF (100 ng/ml cell suspension) were
added  to  each  cell  culture  flask  immediately  and every  other  day for  inducing  the
differentiation of monocytes into  MoDC  (69, 70). DMSO was added to the negative
control  and IL-10  (10 ng/ml  cell  suspension) was added to  the  positive control  for
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altering (stunting) that differentiation (71, 72). Bortezomib was also added to one of the
flasks for comparison (see Table 3.1.4). The cells were incubated for 7 days at 37 °C
and 5 % CO2. 
3.1.4 Administering Carfilzomib and Bortezomib
On the day before harvesting the MoDC were subjected to varying doses of carfilzomib
in DMSO solution and its medical grade equivalent in 5 % glucose solution. The doses
were administered by using new cell culture medium enriched with IL-4 and GM-CSF
and adding the desired dose. The cells were separated from their medium via centrifuge.
The  medium  was  preserved  so  the  cells  could  be  re-suspended  in  their  previous
microenvironment after having been subjected to carfilzomib. The MoDC were then
suspended  in  the  carfilzomib  medium  and  incubated  at  37  °C  and  5  %  CO2 for
60 minutes. After incubation they were taken out of the flasks again and separated from
the carfilzomib via centrifuge. During centrifugation the flasks were rinsed with 10 ml
of  RPMI  medium  which  was  then  added  to  the  cells  for  another  5  minutes  of
centrifugation. Afterwards, the cells were re-suspended in the preserved medium. For
the carfilzomib concentration and duration of exposure, we oriented ourselves according
to previous studies on the IC50 concentration in multiple myeloma cell lines and the
pharmacokinetics of carfilzomib (58, 73, 74). The Protocol for bortezomib was chosen
in accordance with the previous publication (65) by adding the desired dose directly into
the flask (see Table 3.1.4). LPS was added to the MoDC that were designated to become
mature MoDC (mMoDC) (75) 16 hours before the cell harvest. The cells without LPS
were labeled immature MoDC (imMoDC).
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Table 3.1.4: Trial Set-up
1 2 3 4 5
Day 0,2,4,6 IL-4/GM-
CSF
IL-4/GM-
CSF
IL-4/GM-
CSF
IL-4/GM-
CSF
IL-4/GM-
CSF/IL-10
Day 6 DMSO
(+LPS)
100nM
carfilzomib
(+LPS)
100nM
Kyprolis
(+LPS)
1ng/ml
bortezomib/2
4 h (+LPS)
(+LPS)
Day 7                                                Harvest
3.1.5 Harvesting MoDC
The  first  step  was  separating  the  cells  from  the  culture  fluid  via  centrifugation,
preserving some of the culture fluid for immunoassays and re-suspending the cells in
PBS. The internal surface of the culture flasks was also rinsed with 10 ml of room
temperature PBS to release as many cells as possible from it. This was added to the
remaining culture fluid and centrifuged again. The MoDC yield was different each time
and the amount of PBS, usually between 2 ml and 5 ml, was chosen according to the
cell pellet size. The total MoDC count was then determined with the same method used
for  determining  the  PBMC  count  (see  3.1.2)  with  the  only  differences  being  the
concentration of cell suspension (which was 1:2) and the varying amount of PBS (fixed
at 40 ml for the PBMC count) : 
Cellcount · 0.5 · VolumePBS · 2 · 104 
The preserved culture fluid (four 1 ml portions) was labeled and frozen at -20 °C.
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3.2 Flow Cytometry
Flow  cytometry  is  a  technological  method  which  is  used  to  determine  size  and
properties of microscopic particles, e. g. cells. Its analytic potential can be enhanced by
labeling  the  particles  with  fluorescent  markers.  An  example  for  the  non-enhanced
method  would  be  a  regular  blood  count,  a  blood  panel  frequently  requested  by
physicians. Fluorescence-activated cell  sorting (FACS) is  used less frequently in the
medical field, e. g. in HIV staging diagnostics for determining the CD4+ T cell count,
but plays a significant role in biochemical and medical research because it allows for the
assessment of the type and amount of cellular surface molecules expressed in a cell
population.
The process of FACS flow cytometry can be described as follows:
A sample  of  fluorescence  labeled  cells  suspended  in  a  special  buffer  solution  is
gradually aspirated into the flow cytometer. The cells then pass through a tube which
can only accommodate one cell at a time, so single cells can be analysed. During their
transit, the cells are hit with a focused laser beam, and two types of the resulting light
scatter are recorded by detectors: The forward scatter (FSC) in line with the laser beam
and the side scatter (SSC) perpendicular to the laser beam's path. Depending on the
detected scatter, each cell is directed towards a certain container via electrical charge.
FSC  is  largely  dependent  on  cell  size,  while  SSC  is  determined  by  granularity,
fluorescence, nucleic size and number of vesicles.
3.2.1 Labeling MoDC with Fluorescent Antibodies
To analyse molecular patterns on the surface of MoDC, pertinent molecules have to be
labeled with detectable structures. Each of these molecules requires a specific structure
for labeling, usually an antibody with a radioactive or fluorescent molecule attached. 
To evaluate  the  phenotype of  every  MoDC yield,  fluorescent  antibodies  specific  to
MoDC surface  molecules  were  used,  some  of  which  are  crucial  for  proper  MoDC
function.
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Table 3.2.1: FACS Antibodies – Target and Colour
Molecular Target Colour
IgG1 FITC, PE, APC
IgG2b PerCP
CD1a FITC
CD80 FITC
CD83 PE
Osteoaktivin PE
CCR7 PE
CD14 PerCP
DC-SIGN PerCP, (FITC, PE, APC for single stain compensation)
HLA DR APC
CD86 APC
After transferring anywhere from 0.5 · 106 to 106 cells of each type into flow cytometry
tubes, the unspecific binding sites had to be blocked with an FcR blocking agent. After
10 – 20 minutes of dark incubation, these cell amounts were divided into thirds. Each
third was then stained with a mixture of 4 antibodies with different fluorescent colours:
FITC, PE, PerCP and APC.
Some of these colours have overlapping light spectra, which is why single stains with
these colours were necessary for every MoDC phenotype in every trial. These single
stained cells were fed into the flow cytometer to adjust its settings just before the actual
multi-stain analysis. The difference in median fluorescence intensity (DMFI) between
isotype control and a specific molecule served as a stand-in value for the expression of
the analysed surface molecule.
For  better  comparability  between  trial  runs,  I  calculated  the  normalized  DFMI  by
dividing the DMFI of the treated cells by the DMFI of the untreated cells for each trial.
Example:        
DMFIimMoDC/IL-10 / DMFIimMoDC/DMSO
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3.3 Enzyme-Linked Immunosorbent Assay (ELISA)
An enzyme-linked immunosorbent assay, usually better known as ELISA, is a method
by which a specific constituent of a solution can be detected and identified via change in
colour or light emission. There are different types of ELISA, but they work in a similar
fashion: A specific antibody or antigen attached to a surface binds to the molecule which
is  supposed  to  be  detected.  The  surface  is  subsequently  rinsed  of  the  unbound
substances, then an enzyme-conjugated antibody is introduced which also binds to the
detected  and  bound constituent.  After  rinsing  off  the  excess  amount  of  this  second
antibody, the enzyme receives a suitable substrate to produce colour, fluorescence or
light which can then be quantified by measuring the light extinction in comparison to a
dilution series of a known standard.
The ELISA assays used in  this  project  were sandwich-ELISA: The surface-attached
agent  was  a  so-called  capture  antibody  and  the  second  an  enzyme-linked  detection
antibody. In this kind of ELISA the detection antibody and the capture antibody have to
bind to mutually exclusive epitopes to prevent one antibody from interfering with the
binding of the other. In the following paragraph the procedure will be explained in detail
on the basis of one example.
The plate wells were pre-coated with a capture antibody. After preparing the buffer,
substrate solution and cytokine standard according to instructions, the cytokine standard
and the buffer were used to create a dilution series through which concentration and
optical density could be correlated on the resulting graph. 
200 µl of standard, control or sample were added into each plate well, then incubated at
room temperature for 2 hours. After washing three times and removing the liquid, 200
µl of detection antibody solution were added into each well. After 1 hour of incubation
the  washing  procedure  was  repeated  and  the  excess  liquid  removed.  200  µl  of  the
substrate solution was then added into each well. After 20 minutes of dark incubation at
room temperature 50 µl of Stop solution were added into each well. The optical density
was analysed with a microplate reader at a 450 nm wavelength within 30 minutes.
The purpose of the ELISA method in the context of determining MoDC function was to
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quantify MoDC cytokine production after exposure to carfilzomib. 
Table 3.3: Measured Cytokines and Their Functions
Cytokine Function
MIP-1α/CCL3 Inflammation, acute phase-, fever inducing
Rantes/CCL5 Promotes T cell immunity
IL-12 Granulocyte activation,  promotes release of IL-1,  IL-6,
TNF
IL-6 Attracts immune cells to inflammation focus
MCP-1/CCL2 Attracts immune cells to inflammation focus
3.4 Cell Viability
3.4.1 Annexin / Propidium Iodide (PI) staining of MoDC
The annexin-V-fluorescein / PI staining assay can be used for assessing cell viability.
Annexin  is  a  compound  that  binds  to  phospholipids,  especially  phosphatidylserine,
which exclusively occur on the inner, cytoplasm-facing leaflet of a cell’s membrane. It
is “flipped” to the outer leaflet during early apoptosis (76). PI is a dye which binds to
the DNA. As it cannot pass through intact cell membranes, it only stains cells with a
ruptured cell membrane which is a characteristic of both necrosis and late apoptosis
(77). 
In a 96 flat well plate the cell amount per well was 105 MoDC in cell culture medium
with 4 wells per MoDC type, one of which was used for unstained and single stain
annexin and PI. The unstained and single stain cells were used for adjusting voltages
and compensation.  The negative control MoDC had to be divided among 3x4 wells
because of internal negative and positive control MoDC. The internal positive control
for  the  assay  was  done  by  adding  staurosporine  to  each  well,  the  negative  control
consisted of adding DMSO. The plate was then incubated for 20-24 h at 37 °C and 5 %
CO2.  After incubation the cells were harvested and transferred into FACS tubes and
centrifuged, the supernatants were discarded. The cells were then re-suspended in the
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annexin incubation buffer and stained with either annexin-V-Fluos, PI (for the single-
stain)  or  both  (the  other  cells).  After  15 minutes  of  dark  incubation  the  cells  were
immediately analysed via flow  cytometry. Cells further right on the x axis in the Q3
quadrant (lower right) have taken up more annexin than the unspecific amount in the Q4
(lower left) quadrant. This signifies early apoptosis. Cells also higher up on the y axis
inside the Q2 (upper right) quadrant have taken up more PI than the unspecific amount
in  Q3 and Q4.  The percentage  given in  each quadrant  is  the  fraction  of  all  events
recorded  in  that  quadrant.  Cells  in  the  Q4  quadrant  have  only  taken  up unspecific
amounts of annexin and PI, not signifying early or late apoptosis.
3.4.2 Annexin / Propidium Iodide staining of U266 Cells
The annexin / PI stain of the U266 multiple myeloma cells was conducted in the same
manner as the MoDC stain (see chapter 3.4.1) but with different cell yields: 5·105 per
well  for 24 well plates and 1.5·106 per well  for 6 well plates. The U266 cells were
subjected to varying concentrations of carfilzomib in its compound- as well as in its
medical  grade version and bortezomib in accordance with their  respective protocols
before being processed in this assay. 
3.5 Migration towards CCL19/MIP-3β
The migratory capacity of imMoDC and mMoDC was assessed by making them pass a
micro-pore cell culture insert. 
After the MoDC harvest 6·105 cells were re-suspended in RPMI cell culture medium at
a concentration of 2·105/ml. Each well of a 24 flat well plate was filled with 1 ml of
RPMI  cell  culture  medium  enriched  with  CCL19/MIP-3β  at  a  concentration  of
100ng/ml. The next step was to place cell culture inserts with 8 µm pores into the plate
wells and fill them with 1 ml of the preciously prepared cell suspension – 3 plate wells
for each MoDC type. Cell migration along chemotactic gradients also occurs in vivo. A
well  known example  for  this  would  be  leukocytes  leaving the  bloodstream through
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more permeable blood vessels at an inflammation site.
After  16  hours  of  incubation  at  37  °C and  5  % CO2,  the  cell  culture  inserts  were
removed and discarded. The fluid in the plate wells was then transferred into FACS
tubes.  Each  plate  well  was  rinsed  with  its  contained  fluid  once  to  loosen  MoDC
adherent to the bottom of the well. The cells were centrifuged for 5 minutes at 1500 rpm
and re-suspended in flow cytometry buffer. The amount of cells aspirated during the
course of 60 seconds was then measured with the flow cytometer. The cell count is a
stand-in  value  for  the  migrated  cells  (not  all  of  the  cells  are  aspirated  within
60 seconds).
3.6 Freezing Cells
MoDC can be preserved for later use by freezing them at -80 °C in a freezing medium
consisting of FCS with a 10 % volume fraction of DMSO. After counting the MoDC in
PBS and subsequent centrifugation, the cells have to be re-suspended in the freezing
medium at a cell concentration which is equal to or below 107/ml. The transfer into the
special freezing tubes as well as the transfer of those tubes into the freezing container
and the transport to the -80 °C freezer all have to happen quickly because of DMSO
toxicity at warmer temperatures. The freezing container is filled with isopropyl alcohol
which cools the cells by -1 °C/min approximately. After having been completely frozen,
the cells may be stored in another container.
3.7 Thawing Cells
Before thawing the frozen cells, 20 ml of the right cell culture medium were heated to
37 °C. With a 1000 µl pipette the solid block of frozen cell suspension were dissolved in
the  warm  medium  and  centrifuged  quickly  because  of  the  aforementioned  DMSO
toxicity. After discarding the supernatant, the pellet was re-suspended in another 20 ml
of warm medium and centrifuged again. The cells were then be re-suspended in 5-10 ml
of medium, counted and sown into the appropriate cell culture container. 
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3.8 Cultivating the Non-Adherent U266 Multiple Myeloma Cells
After thawing the U266 cells, suspending them in RPMI (+FCS) medium and seeding
them out at 0.5·106/ml, the cell population was split regularly because the cells consume
the medium for their infinite replication cycles. The cell count was determined (also in
the Neubauer chamber but suspended in their culture fluid instead of PBS) for the first
few splits. After discarding about 2/3 of the cell amount, the cells are then provided with
fresh medium. This step has to be repeated within 2 days after the last split for as long
as the cell culture is supposed to be maintained. The cells were incubated at 37 °C and
5 % CO2; their concentration did not exceed 106/ml. The medium and the method of
sowing the  cells  were  done according to  instructions  given by the  Leibniz  Institute
DSMZ-German Collection of Microorganisms and Cell Cultures GmbH.
3.9 Statistical analysis
Each  experiment  was  realized  at  least  three  times  revealing  similar  results.
Representative  experiments  as  well  as  combined  data  are  shown.  If  not  otherwise
declared, technical triplicates were performed leading to an average value and enabling
the  calculation  of  a  standard  error  of  the  mean.  To  prove  statistical  significance
Dunnett’s test was applied if not otherwise declared; p values < 0.05 were considered
suggesting statistical significance. Values deviating more than two standard deviations
from the mean were considered outliers and excluded from the final analysis. Statistical
analysis was performed with SAS JMP 13 for Windows.
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4. Results
The  objective  of  this  project  was  on  discovering  a  possible  change  in  the  MoDC
phenotype due to carfilzomib. MoDC function was tested with regard to cell viability,
cytokine secretion and migration. Asterisks signify statistical significance.
4.1 Cell Viability
These  trials  were conducted  to  find  a  dosage  that  is  sufficiently  high  for  myeloma
treatment while maintaining a low degree of MoDC toxicity.
4.1.1 Higher Doses of Carfilzomib Induce Apoptosis in MoDC
Proteasome inhibition  facilitated  by  carfilzomib  does  not  selectively  target  multiple
myeloma cells,  and therefore an effect  on cell  viability  of  normal  cells  is  possible.
Analysis in an annexin / propidium-iodide assay for assessment of apoptosis and cell
death showed a decrease in MoDC viability after exposure to the 300 nM carfilzomib
dosage, especially if the cells were stimulated with LPS thereafter (see figure 4.1.1 a).
The trials with 300 nM carfilzomib had to be discontinued because they did not yield
the minimal amount of cells required for analysis. The majority of mMoDC treated with
300 nM carfilzomib showed an increase in annexin uptake indicating early apoptosis.
The non-stimulated imMoDC also showed an increase in annexin uptake after exposure
to the same amount of carfilzomib.
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Figure 4.1.1 a: Example of flow cytometry dot plots following an annexin / PI assay with MoDC. Cells further right
on the x axis in the Q3-quadrant have taken up more annexin than the unspecific amount in the Q4 quadrant. This
signifies early apoptosis. Cells that are also higher up on the y axis and have entered the Q2 quadrant have taken up
more PI than the unspecific amount in the Q3 and Q4 quadrants indicating membrane integrity loss (end stage
apoptosis). The percentages given in each quadrant is the fraction of all events recorded in that quadrant. N=2
The 100 nM dosage of carfilzomib and Kyprolis appeared to be considerably less toxic
with respect to apoptosis and necrosis. The yield of viable cells was much closer to the
DMSO control (see figure 4.1.1 b). Compared to the DMSO control, there is only a
small increase in annexin or annexin and PI uptake in both imMoDC and mMoDC after
exposure to 100 nM carfilzomib or Kyprolis.
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Figure 4.1.1 b: Example of flow cytometry dot plots following an annexin / PI assay with MoDC. Cells further right
on the x axis in the Q3-quadrant have taken up more annexin than the unspecific amount in the Q4 quadrant. This
signifies early apoptosis. Cells higher up on the y axis in the Q2 quadrant have taken up more than the spontaneous
amount of PI in the cells of the Q3 and Q4 quadrants. The percentages given in each quadrant is the fraction of the
all events recorded in that quadrant. . N=3
4.1.2 Effect of Carfilzomib Dosage on Viabilty of Myeloma Cell Line U266
To find out how the 100 nM dosage of of carfilzomib and Kyprolis would compare to
higher dosages in terms of an anti myeloma effect, we compared dosages up to 1000 nM
carfilzomib in an annexin / propidium-iodide assay with cells from a U266 multiple
myeloma cell line. The non-medical grade compound was compared with the medical
grade compound Kyprolis to compensate for possible impurities or byproducts in the
non-medical  grade  compound  as  confounding  factors.  There  seemed  to  be  little
difference between combined percentages of all apoptotic cells in the cells treated with
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100 nM, 300 nM and 1000 nM carfilzomib. Kyprolis seemed to be less potent than the
chemical compound. 30 nM carfilzomib appeared to be inferior regarding induction of
apoptosis  in vitro. The 1 ng/ml (2.6 nM) bortezomib dosage seemed to be inferior to
30 nM carfilzomib in  this  regard.  All  of  these  trials  were  conducted  with the  same
carfilzomib  lot.  All  of  the aforementioned  results  were  statistically  significant  in
one-tailed t-tests (p<0.05).
Figure 4.1.2 a: Example of flow cytometry dot plots following an annexin / PI assay with U266 multiple myeloma
cells. Cells further right on the x axis in the Q3-quadrant have taken up more annexin than the unspecific amount in
the Q4 quadrant. This signifies early apoptosis. Cells also higher up on the y axis inside the Q2 quadrant have taken
up more PI than the unspecific amount in Q3 and Q4. The percentage given in each quadrant is the fraction of all
events recorded in that quadrant. N=3
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Figure 4.1.2 b: Example of flow cytometry dot plots following an annexin / PI
assay with U266 multiple myeloma cells. Cells further right on the x axis in the
Q3-quadrant have taken up more annexin than the unspecific amount in the Q4
quadrant.  This signifies early apoptosis. Cells also higher up on the y axis
inside the Q2 quadrant have taken up more PI than the unspecific amount in
Q3 and Q4. The percentage given in each quadrant is the fraction of all events
recorded in that quadrant. N=3
100nM carfilzomib was identified to be effective in induction of apoptosis  in U266
myeloma cell line cells in vitro while limited toxicity in MoDC was observed which is
why consecutive experiments were focused on the 100 nM carfilzomib dosage. 
4.2 MoDC Phenotype
MoDC were treated with100 nM carfilzomib on day 6 of  the cell  culture.  Possible
changes  of  the  MoDC phenotype after  exposure  on  day  6  were  detected  by  FACS
analysis on day 7. In the following experiments the effects of 100 nM carfilzomib on the
phenotype  of  MoDC  was  assesed.  A  phenotype  baseline  can  be  established  by
compiling overlays of DMSO treated MoDC (see figure 4.2). IL-10 served as a positive
control because it hampers differentiation of monocytes into MoDC (78). 
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Figure  4.2: Normal  Phenotype  of  Untreated  imMoDC  and  mMoDC.  Row  1-2:  untreated  imMoDC,  row  3-4:
untreated mMoDC; X-Axis: Surface expression; y axis: cell count; red: IgG-isotype; blue: phenotype
4.2.1 Exposure to Carfilzomib Does Not Affect the Expression of CD14 in MoDC
CD14 is a surface molecule especially found on monocytes. In this line of experiments
the loss of CD14 expression signifies the successful differentiation of monocytes into
MoDC (see figure 4.2.1 a-c). The cells treated with IL-10 served as positive control, the
ones treated with DMSO as negative control. As shown in Figures 4.2.1 a-c, treatment
of MoDC with 100 nM carfilzomib had no significant effect on CD14 expression while
higher maintained CD14 expression in IL-10 treated cells could be observed (p<0.05). 
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Figure 4.2.1 a: ImMoDC and mMoDC were stained with a fluorescent anti-CD14, then analysed via flow cytometry.
The histograms in this example show very low expression of CD14 as would be expected from MoDC. Cells treated
with IL10 showed higher CD14 expression. Top row: imMoDC, bottom row: mMoDC; X-Axis: CD14 expression;
y axis: cell count; red: IgG-isotype; blue: CD14
Figure 4.2.1 b: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC. Columns  left  to  right:
DMSO, 100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=8 
Figure 4.2.1 c: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
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4.2.2  Exposure  to  Carfilzomib  Does  Not  Affect  the  Expression  of  CD1a  in
Unstimulated or LPS Stimulated MoDC
CD1a is a surface protein, which, like the structurally related MHC proteins, is involved
in antigen-presentation. It is also a marker for IL-12 secreting DC (79). Carfilzomib and
Kyprolis exposure had no statistically significant effect on the expression of the CD1a
molecule in unstimulated or LPS stimulated mMoDC while  exposure to bortezomib
produced a statistically significant decrease in imMoDC and mMoDC (see figure 4.2.2 a
and b; p<0.05). For mMoDC, but not for imMoDC, this has been demonstrated in our
previous study (65).
Figure 4.2.2 a: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
Figure 4.2.2 b: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=9
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Figure 4.2.2 c: Exemplary overlay of a CD1a trial. Top row: imMoDC; bottom row: mMoDC; y axis: cell count; red:
IgG-isotype; blue: CD1a
4.2.3 Exposure to Carfilzomib Does Not Affect the Expression of CD209/DC-SIGN
in Unstimulated or LPS Stimulated MoDC
As a  C-type  lectin  receptor,  CD209/DC-SIGN recognizes  mannose  based  microbial
PAMPs (80). Neither Carfilzomib nor Kyprolis had a statistically significant effect on
the expression of DC-SIGN/CD209 in unstimulated or LPS stimulated mMoDC (see
figure  4.2.3  a  and  b;  p>0.05)  while  bortezomib  exposure  produced  a  statistically
significant decrease in LPS stimulated mMoDC (see figure 4.2.3 b; p<0.05) which has
also been demonstrated in our previous study (65).
Figure 4.2.3 a: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
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Figure 4.2.3 b: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
Figure 4.2.3 c: Exemplary overlay of a DC-SIGN/CD209 trial. Top row: imMoDC; bottom row: mMoDC; y axis: cell
count; red: IgG-isotype; blue: DC-SIGN/CD209
4.2.4 Exposure to Carfilzomib Decreases Expression of CD83 in LPS Stimulated
mMoDC
CD83 is a surface protein that can almost exclusively be found on MoDC which have
completed  the  maturation  process.  It  plays  an  important  role  in  facilitating  T  cell
immunity and proliferation (see chapter 1.1.5). It was previously shown that bortezomib
exposure decreases CD83 expression in LPS stimulated mMoDC and has no effect on
its expression in unstimulated imMoDC (65). In this line of experiments, a decrease in
CD83 expression average could be observed for the LPS stimulated mMoDC treated
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with  30  nM  carfilzomib,  100  nM  carfilzomib,  100  nM  Kyprolis,  1 ng/ml
bortezomib/24 h and the IL-10 positive control (see figure 4.2.4 a and c). The decrease
of expression was not statistically significant for the 30 nM carfilzomib treatment group
(not  shown).  For  every  other  group  the  change  was  significant  (p<0.05).  For
bortezomib, this had already been demonstrated in our previous study (65). In imMoDC
there  was  no  significant  decrease  after  carfilzomib  exposure.  Bortezomib  exposure
caused a statistically significant up-regulation of CD83 in imMoDC, which is not in line
with our previous study (see figure 4.2.4 a and b; p<0.05).
Figure 4.2.4 a: MoDC were stained with a fluorescent anti-CD83, then analysed via flow cytometry. The histograms
in this example show a increase in cells with lower expression of CD83 after treatment with carfilzomib and Kyprolis
as well as after bortezomib treatment. Top row: imMoDC; bottom row: mMoDC; X-Axis: CD83 expression; y axis:
cell count; red: IgG-isotype; blue: CD83
Figure 4.2.4 b: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO, 100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=8
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Figure 4.2.4 c: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10 
4.2.5  Exposure  to  Carfilzomib  Increases  Expression  of  CD80  in  Unstimulated
imMoDC but Decreases Its Expression in LPS Stimulated mMoDC
The protein CD80 on the surface of MoDC is an important co-stimulatory molecule for
activating  T-lymphocytes  (see  also  chapter  1.1.4).  It  was  previously  shown  that
bortezomib exposure decreases CD80 expression in LPS stimulated mMoDC and has no
effect on its expression in unstimulated imMoDC (65). In this line of experiments an
increased expression of CD80 on average could be observed in all imMoDC treatment
groups. This change was statistically significant in the 100 nM carfilzomib, 100 nM
Kyprolis and the IL-10 positive control (see figure 4.2.5 b; p<0.05). In LPS stimulated
mMoDC, the 3 nM carfilzomib treatment group appeared to have increased expression
of CD80 which was not statistically significant. In every other treatment group there
was a statistically significant decrease in CD80 expression average (see figure 4.2.5 c;
p<0.05). This has been demonstrated for bortezomib in our previous study (65).
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Figure 4.2.5 a: ImMoDC and mMoDC were stained with a fluorescent anti-CD80, then analysed via flow cytometry.
The histograms in this example show an increase in imMoDC with higher expression of CD80 after treatment with
carfilzomib and Kyprolis as  well  as  an decrease in  mMoDC with higher expression of CD80 after carfilzomib,
Kyprolis and bortezomib treatment. Top row: imMoDC, bottom row: mMoDC; X-Axis: CD80 expression; y axis: cell
count; red: IgG-isotype; blue: CD80
Figure 4.2.5 b: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO, 100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
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CD80 imMoDC
Figure 4.2.5 c: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
4.2.6  Exposure  to  Carfilzomib  Does  Not  Affect  the  Expression  of  CD86  in
Unstimulated or LPS Stimulated MoDC
CD86 and CD80 both act as ligands for CD28 and are therefore important for priming
T cells  (see  also  chapter  1.1.4).  Neither  carfilzomib nor  Kyprolis had  a  statistically
significant effect on the expression of CD86 in unstimulated or LPS stimulated mMoDC
(see figure 4.2.6 a and b; p>0.05) while bortezomib exposure resulted in a statistically
significant decrease of CD86 expression in LPS stimulated mMoDC (see figure 4.2.6 b;
p<0.05) which is in line with our previous study (65). 
Figure 4.2.6 a: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=9
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Figure 4.2.6 b: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
Figure 4.2.6 c: Exemplary overlay of a CD86 trial. Top row: imMoDC; bottom row: mMoDC; y axis: cell count; red:
IgG-isotype; blue: CD86
4.2.7  Exposure  to  Carfilzomib  Does  Not  Affect  the  Expression  of  HLA-DR in
Unstimulated or LPS Stimulated MoDC
Carfilzomib  and  Kyprolis exposure  had  no  statistically  significant  effect  on  the
expression of the peptide presenting MHC Type II molecule HLA-DR in unstimulated
or LPS stimulated mMoDC. Exposure to bortezomib produced a statistically significant
decrease  of  HLA-DR expression  in  unstimulated  and LPS stimulated  mMoDC (see
figure  4.2.7  a  and  b;  p<0.05).  For  mMoDC,  but  not  for  imMoDC,  this  has  been
demonstrated in our previous study (65).
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Figure 4.2.7 a: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=10
Figure 4.2.7 b: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM  carfilzomib,  100 nM
Kyprolis, 1  ng/ml=2.6 nM bortezomib/
24  h,  IL-10;  y axis:  DMFI;  asterisks
signify statistical significance; N=9
Figure 4.2.7 c: Exemplary overlay of a HLA-DR trial. Top row: imMoDC; bottom row: mMoDC; y axis: cell count;
red: IgG-isotype; blue: HLA-DR
52
HLA-DR imMoDC
HLA-DR mMoDC
4.2.8 Exposure to Carfilzomib Increases the Expression of CCR7 in Unstimulated
and LPS Stimulated MoDC
CCR7  is  an  important  receptor  for  cell  migration  towards  lymph  nodes  (81).  In
imMoDC, 100 nM carfilzomib, but not  Kyprolis,  produced a statistically  significant
increase in CCR7 surface expression (see figure 4.2.8 a; p<0.05) while the increase in
mMoDC  was  not  significant  (see  figure  4.2.8  b;  p>0.05).  Bortezomib  exposure
produced a statistically significant decrease in LPS stimulated mMoDC (see figure 4.2.8
b; p<0.05) which has also been demonstrated in our previous study (65).
Figure 4.2.8 a: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for  DMSO treated
imMoDC.  Columns  left  to  right:
DMSO,  100 nM  carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24  h,  IL-10;  y axis:  DMFI;  asterisks
signify statistical significance; N=6
Figure 4.2.8 b: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=6
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Figure 4.2.8 c: Exemplary overlay of a CCR7 trial. Top row: imMoDC; bottom row: mMoDC; y axis: cell count; red:
IgG-isotype; blue: CCR7
4.2.9  Exposure  to  Carfilzomib  Does  Not  Affect  the  Expression  of
GPNMB/Osteoactivin in Unstimulated or LPS Stimulated MoDC
GPNMB/Osteoactivin  is  a  transmembrane  protein,  which  acts  as  a  coinhibitory
molecule strongly inhibiting T cell responses if present on APC. Our working group has
previously shown that its expression on human MoDC is dramatically upregulated upon
treatment  with IL-10 but  also by BCR-ABL tyrosine kinase inhibitors  (82).  Neither
bortezomib,  nor  carfilzomib  or  Kyprolis had  a  statistically  significant  effect  on  its
expression  in  unstimulated  or  LPS  stimulated  mMoDC  (see  figure  4.2.9  a  and  b;
p>0.05).
Figure 4.2.9 a: Average and standard
deviation  of  the  DMFI  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO, 100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=3
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Figure 4.2.9 b: Average and standard
deviation  of  the  DMFI  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO, 100 nM carfilzomib,  100 nM
Kyprolis, 1 ng/ml=2.6 nM bortezomib/
24 h,  IL-10;  y axis:  DMFI; asterisks
signify statistical significance; N=3
Figure 4.2.9 c: Exemplary overlay of an GPNMB/Osteoactivin trial.  Top row: imMoDC; bottom row: mMoDC;
y axis: cell count; red: IgG-isotype; blue: osteoactivin
4.3 MoDC Function
Carfilzomib Does Not Significantly Impair Migration of MoDC
The ability to migrate is an important requirement for DC to fulfill their purpose of
stimulating T cells in the lymph nodes. The migration assay and subsequent analysis via
flow cytometry did not show a statistically significant change in migratory capacity of
imMoDC or mMoDC after exposure to 100 nM of either carfilzomib or Kyprolis (see
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figure 4.3 a  and b;  p>0.05).  Exposure to 1 ng/ml bortezomib for  24 h lowered the
migratory capacity of LPS stimulated mMoDC to a statistically significant extent which
is consistent with the results of our previous study (see figure 4.3 b; p<0.05). 
Figure  4.3  a: Average  and  standard
deviation  of  the  cell  count  in  each
imMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
imMoDC.  Columns  left  to  right:
DMSO,  100 nM  carfilzomib,
100 nM Kyprolis,  1 ng/ml=2.6  nM
bortezomib/24  h,  IL-10;  y axis:  cell
count;  asterisks  signify  statistical
significance; N=8
Figure  4.3  b: Average  and  standard
deviation  of  the  cell  count  in  each
mMoDC  group.  The  values  were
normalized to 1.00 for DMSO treated
mMoDC.  Columns  left  to  right:
DMSO,  100 nM  carfilzomib,
100 nM Kyprolis,  1 ng/ml=2.6  nM
bortezomib/24  h,  IL-10;  y axis:  cell
count;  asterisks  signify  statistical
significance; N=9
4.4 MoDC Cytokine Secretion
Carfilzomib Affects Cytokine Levels to a Lesser Extent Than Bortezomib
After stimulation and during their maturation process, DC undergo functional changes.
One significant change is the increased secretion of inflammatory cytokines (see chapter
1.1.5).  We  analysed  levels  of  IL-6,  IL-12,  MCP-1/CCL2,  MIP-1α/CCL3  and
Rantes/CCL5 with ELISA assays. The results of these experiments were not statistically
significant except for a decrease in imMoDC MCP-1/CCL2 concentration and mMoDC
MIP-1α (see figures 4.4.1 b and 4.4.2 a). 
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The tendency towards lower cytokine concentrations after bortezomib exposure in LPS
stimulated mMoDC is in line with our prevous study.
Figure 4.4.1 a: Average and standard
deviation  in  the  supernatant  cytokine
concentration of  the  imMoDC group.
The values were normalized to 1.00 for
DMSO treated imMoDC. Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
Figure 4.4.1 b: Average and standard
deviation  in  the  supernatant  cytokine
concentration  of  the  mMoDC  group.
The values were normalized to 1.00 for
DMSO treated mMoDC. Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration;  asterisks  signify
statistical significance; N=7
Figure 4.4.2 a: Average and standard
deviation  in  the  supernatant  cytokine
concentration of  the  imMoDC group.
The values were normalized to 1.00 for
DMSO treated imMoDC. Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
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MCP-1/CCL2 imMoDC
Figure 4.4.2 b: Average and standard
deviation  in  the  supernatant  cytokine
concentration  of  the  mMoDC  group.
The values were normalized to 1.00 for
DMSO treated mMoDC.  Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
Figure 4.4.3 a: Average and standard
deviation  in  the  supernatant  cytokine
concentration of  the  imMoDC group.
The values were normalized to 1.00 for
DMSO treated imMoDC. Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
Figure 4.4.3 b: Average and standard
deviation  in  the  supernatant  cytokine
concentration  of  the  mMoDC  group.
The values were normalized to 1.00 for
DMSO treated mMoDC.  Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=8
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MCP-1/CCL2 mMoDC
RANTES/CCL5 imMoDC
RANTES/CCL5 mMoDC
Figure 4.4.4 a: Average and standard
deviation  in  the  supernatant  cytokine
concentration of  the  imMoDC group.
The values were normalized to 1.00 for
DMSO treated imMoDC. Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
Figure 4.4.4 b: Average and standard
deviation  in  the  supernatant  cytokine
concentration  of  the  mMoDC  group.
The values were normalized to 1.00 for
DMSO treated mMoDC.  Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
Figure 4.4.5 a: Average and standard
deviation  in  the  supernatant  cytokine
concentration of  the  imMoDC group.
The values were normalized to 1.00 for
DMSO treated imMoDC. Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=5
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IL-6 imMoDC
IL-6 mMoDC
IL-12 imMoDC
Figure 4.4.5 b: Average and standard
deviation  in  the  supernatant  cytokine
concentration  of  the  mMoDC  group.
The values were normalized to 1.00 for
DMSO treated mMoDC.  Columns left
to right: DMSO, 100 nM carfilzomib,
100  nM  Kyprolis,  1  ng/ml=2.6  nM
bortezomib/24  h;  y  axis:
concentration; asterisks  signify
statistical significance; N=7
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IL-12 mMoDC
5. Discussion
As crucial  facilitators of communication between innate and adaptive immunity, DC
have been endowed with a comparatively large variety of abilities, several of which
have been examined in this project. Some DC subtypes in peripheral blood are very rare
and difficult to cultivate in monocultures, which is the reason why this project focused
on MoDC. 
Many of the available cancer and myeloma drugs are non-selective and have severe side
effects.  Nowadays,  despite  several  modes  of  treatment  being  available,  multiple
myeloma remains incurable in most cases. We used this in vitro model to examine the
effects  of  carfilzomib  on  MoDC to  asses  the  viability  of  a  combined  approach  to
myeloma treatment, which has the potential to mitigate the severe side effects of current
tumour  therapy  regimens  by  using  vaccination  to  achieve  the  goal  of  a  long-term
immune response and disease remission. Nencioni  et al. had previously demonstrated
several  detrimental  effects  of  bortezomib  on  MoDC  function:  It  affected  MoDC
activation  and  viability  (64),  caused  reduced  levels  of  RelB2,  reduced  levels  of
phosphorylated  p42/ERK2  belonging  to  the  MAP kinases  and  interferon  regulatory
factor pathway as well as decreased expression of MyD88 which interacts with MAP
kinases  and  NF-κB  pathway  activating  kinases;  skewed  phenotypic  maturation,  a
decline  in  migration  towards  CCL19/MIP-3β,  lower  stimulatory  capacity  and  less
secretion of IL-12 and TNF were also observed (65). In imMoDC, bortezomib exposure
resulted  in  lower  endocytic  capacity  and  less  expression  of  the  CD206  mannose
receptor (65). 
The study was designed to contrast the previously demonstrated effects of proteasome
inhibition via bortezomib on MoDC to that of proteasome inhibition via carfilzomib
with IL-10 serving as a positive control. LPS is an archetypal DC stimulus and induces
a  phenotypic  activation  via  the  TLR4  and  NF-kB  signal  transduction  pathway.
Therefore  it  was  used  as  maturation  stimulus  despite  its  bacterial  origin  because  it
causes the desired response with increased secretion of inflammatory IL-12 and T cell
2 A transcription factor interacting with NF-κB.
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differentiation leaning towards Th1 cells which then leads to the increased CD8+ T cell
and NK cell toxicity desirable for a potential tumour therapy (83). 
To find a suitable carfilzomib dosage for the MoDC functional analysis we conducted
cell viability assays and found that 300 nM carfilzomib would be too toxic and used
100 nM instead which yielded better  results  (see chapter  4.1.1).  For  bortezomib we
chose a dosage that had affected the MoDC phenotype in previous publications.
We also compared the  in vitro anti-myeloma effect of bortezomib and carfilzomib on
the U266 multiple myeloma cell line and found rates of apoptosis ranging from 74.8 %
to 96.6 % for the 100 nM carfilzomib group, 54.2 % to 79.8 % for the 100 nM Kyprolis
group and 16.3 % to 32.6 % for the 1 ng/ml (2.6 nM) bortezomib group. The main
difference between 100 nM and 300 nM carfilzomib exposure was the percentage of
cells which had already progressed from early to late apoptosis at the time of analysis.
There seemed to be no noticeable difference in induction of apoptosis between 1000 nM
carfilzomib and 300 nM carfilzomib. The 30 nM carfilzomib dosage was inferior to
higher  dosages with regard to induction of apoptosis.  100 nM of the medical grade
Kyprolis seemed to be slightly inferior to the chemical compound. These results suggest
bortezomib being inferior to carfilzomib in terms of  in vitro anti-myeloma effect in a
dosage which is already detrimental to MoDC function. Minor differences between the
two types of carfilzomib can be explained by the fact that samples of the medical grade
carfilzomib  could  only  be  obtained  after  a  patient’s  intravenous  infusion  had  been
completed and the fluid remaining in the infusion tube could be extracted. At that time,
the drug had been exposed to light and room temperature,  which may have slightly
lowered the amount of active molecules.  Another possible explanation would be the
medical grade carfilzomib being dissolved in 5 % glucose solution and the non-medical
grade agent being dissolved in DMSO.
Carfilzomib  caused  some  statistically  significant  changes  to  the  MoDC  phenotype.
However, the changes were considerably less pronounced than the ones caused by its
predecessor  bortezomib  despite  its  comparatively  higher  apoptotic  effect  in  the
myeloma cell culture. The DMSO treated MoDC yielded populations with the regular
phenotype and could therefore be used as the reference to which other treatment groups
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had to be compared. Except for IL-10 which caused a statistically significant increase,
CD14 expression remained almost unchanged for all substances as would be expected
after successful differentiation into MoDC. DC-SIGN/CD209 and CD1a as DC markers
were  not  affected  by  carfilzomib while  bortezomib caused  a  statistically  significant
down-regulation in both. Expression of the antigen-presentation molecule HLA-DR was
unaffected  by  carfilzomib  but  negatively  affected  by  bortezomib  exposure  to  a
statistically significant extent. 
In  imMoDC  carfilzomib  and  Kyprolis  exposure  caused  a  statistically  significant
up-regulation of CD80. This, however, was a minor change to a low level of expression
and  might  therefore  be  irrelevant.  In  mMoDC  carfilzomib  and  Kyprolis exposure
caused a statistically significant down-regulation of CD80 and CD83. 
Bortezomib  exposure  caused  a  statistically  significant  up-regulation  of  CD83  in
imMoDC  and  a  statistically  significant  down-regulation  of  CD80  and  CD83  in
mMoDC. In the imMoDC carfilzomib groups, CD80 was up-regulated to a statistically
significant  extent.  DC  that  show  a  disparity  in  functional  maturation  have  been
described as semi-mature with an up-regulation of co-stimulatory molecules without
any relevant cytokine secretion and have been reported to cause T cell  anergy  (84).
Since this may cause vaccines to be less effective, further research would be required to
determine whether this effect is substantial enough to increase the tolerogenic effect of
iDC.  Additional  research  into  this  might  also  be  useful  in  the  context  of  possible
treatments for autoimmune diseases. 
Down-regulation of CD83 in DC has  been associated with lower capacity  to  prime
CD8+ T cells for specific tumour antigens, with less induction T cell proliferation and a
decrease  in  T cell  IFN-γ  secretion  (15).  As  this  would  be  undesirable  when  using
vaccines,  carfilzomib may be less  adverse in a  combined therapeutic  approach than
bortezomib because the effect on CD83 expression was much weaker than that of its
predecessor. Looking at the expression of CD80 – an important co-stimulatory molecule
for T cell activation – the difference between the two substances was less pronounced.
Bortezomib exposure also caused a statistically significant down-regulation of CD1a
and HLA-DR in imMoDC and a statistically significant down-regulation of all analysed
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surface molecules except osteoactivin in mMoDC. Carfilzomib exposure also caused a
statistically  significant  up-regulation  of  CCR7 which  did  not  result  in  a  noticeable
increase in migrated cells.
All findings regarding the mMoDC phenotype after bortezomib exposure are consistent
with our previous publications (65).
Bortezomib  was  almost  similar  to  IL-10  in  the  mMoDC  migration  assay  while
carfilzomib did not significantly change the CCR7-mediated migration when compared
to untreated cells. This is especially desirable when using non-cellular vaccines meant
to  stimulate  DC  in  vivo.  Ex  vivo generated  DC may  have  little  to  no  carfilzomib
exposure, and that is why this finding may be less relevant for those vaccines. 
Analysis  of  MoDC cytokine  secretion  showed  a  statistically  significant decrease  in
imMoDC MCP-1/CCL2 concentration and mMoDC MIP-1α/CCL3 concentration after
bortezomib exposure.  Rantes/CCL5 and the  aforementioned cytokines  are  important
factors produced at inflammation sites (85–87). One of their main functions is attracting
and recruiting additional leukocytes. In contrast to that, IL-6 and IL-12 are cytokines of
systemic  inflammation  and  therefore  complex  in  their  functions  (88,  89).  For  all
cytokines analysed, a consistent trend of higher cytokine expression for LPS stimulated
mMoDC after carfilzomib or Kyprolis exposure in comparison to bortezomib exposure
could  be  observed.  The  results  were  not  statistically  significant  but  lower  cytokine
concentration after bortezomib exposure is in keeping with our previous results  (65).
These results not being statistically significant may be a donor-dependent phenomenon
or due to the number of experiments performed. There have been previous studies with
conflicting results regarding MoDC function after bortezomib exposure: Some confirm
the drug having a detrimental effect on different aspects of MoDC function  (65, 90)
while other results provide evidence for an augmented DC driven immune response to
different tumour entities after exposure to it (91). In vivo experiments seem to support
the  former  (92) which  makes  the  discussion  about  using  proteasome  inhibitors  for
immunomodulation a  controversial  one.  There is  also evidence suggesting a clinical
benefit  using  bortezomib  in  the  treatment  of  graft-versus-host  disease  which  might
originate  from  its  modulating  effect  on  DC function  and  its  potential  to  attenuate
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immune reactions (93, 94).
Systemic therapy of multiple myeloma could certainly be the origin of DC dysfunction
but the disease itself has similar potential  to be the cause. It has been reported that
plasmacytoid and myeloid DC accumulate in the bone marrow where the myeloid DC
interact with CD28 on myeloma cells which causes the tumour cells to down-regulate
expression  of  intracellular  proteasome  structures  associated  with  HLA type  I  and
thereby lead to myeloma cells more easily avoiding CD8+ T cell killing (66). One could
speculate  this  to  be  a  reason for  the  so  far  unsatisfactory  results  of  vaccination  in
multiple myeloma therapy. Abatacept,  a CTLA-4 fusion protein which competitively
inhibits CD80/CD86 binding to CD28 and is primarily used to treat rheumatoid arthritis
(95),  is already being incorporated in current studies  (96) to offset  the resistance to
chemotherapy which is also facilitated by CD28 expressed on myeloma cells  (97) and
could  lead  to  better  patient  outcomes  not  just  because  of  better  response  to
chemotherapy  but  also  to  tumour  vaccines. Carfilzomib  does  not  specifically  target
multiple myeloma cells  and could therefore be used in treatment regimens for other
tumours. An anti-tumour effect against mantle cell lymphoma has been demonstrated in
vitro and in a mouse model (98). Some breast cancer cell lines also responded well to
carfilzomib in combination with other treatments  in vitro (99–101). Pre-clinical trials
with  carfilzomib in  anaplastic  thyroid cancer,  non-small-cell  lung cancer  as  well  as
small-cell lung cancer and colorectal cancer (102–104) have been somewhat promising
as well as models with improved micellar carfilzomib in non-small-cell lung cancer cell
lines and multiple myeloma  (105). The results of this project would therefore also be
pertinent when considering combined immunotherapeutic approaches, e.g. in non-small-
cell lung cancer (106).
Other  effects  of  proteasome  inhibition  via  carfilzomib  include  micro-environmental
changes through induction of apoptosis in cancer associated fibroblasts of other cancer
entities (107) as well as the aforementioned alteration of the HLA-presented peptidome
(see chapter 1.3) which was demonstrated by Kowalewski et al. using the same time of
exposure to and concentration of carfilzomib that was used in this project  (68). To be
able to estimate possible clinical benefits of myeloma vaccines in patients undergoing
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carfilzomib  treatment,  effects  of  the  altered  peptidome  on  the  immunogenicity  of
multiple myeloma cells have yet to be analysed.
To  this  day  most  types  of  cancer  present  a  therapeutic  challenge.  Most  patients  in
advanced stages can neither receive a definitive cure nor can their disease be perpetually
stabilized. The immune system is an important part of what has to be a multimodal
approach to treating a very heterogeneous disease. 
In this project we have established that carfilzomib, as opposed to bortezomib, has very
little effect on the phenotype of MoDC in vitro. Its effect on MoDC function with regard
to  cytokine  secretion  and  migration  compares  favourably  to  its  predecessor.  This
suggests that combining tumour vaccination with carfilzomib may be more viable than
using bortezomib in this manner. It also suggests that the immune system in patients
treated with carfilzomib may be less iatrogenically compromised than in patients treated
with bortezomib. T cell assays analysing the de facto allostimulatory function of MoDC
after carfilzomib exposure could be conducted for further research into possible effects
on DC. Further clinical and preclinical trials will be needed before making definitive
statements.  Extracting primary blood DC from patients treated with carfilzomib and
analysing the viability, phenotype and function could also be a worthwhile avenue of
research. 
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6. Summary
DC are the most potent APC and as such among the most  important links  between
innate and the adaptive immunity. This is in part due to their unique ability to cross-
present  via  MHC I and MHC II and prime naive CD8+ T cells  with co-stimulatory
molecules.  Their  abilities  are  vital  for  their  use  in  the  development  of  therapeutic
vaccines. Carfilzomib is a second-generation proteasome inhibitor used for treatment of
multiple  myeloma.  With  multiple  myeloma  being  incurable,  achieving  remission
combining  carfilzomib  with  long  lasting  disease  control  via  well  tolerated  antigen-
specific  tumour  vaccines  could  be  an  alternative.  In  the  present  work  MoDC were
generated in vitro and cell viability assays were used to determine a suitable dosage for
MoDC functional analysis and for determining whether the chosen dosage of 100 nM
had enough in vitro anti-myeloma effect. The phenotype of the MoDC was analysed by
fluorescent  antibody  labeling  for  several  surface  molecules  and  analysis  via  flow
cytometry. In mMoDC, carfilzomib caused a statistically significant decrease in CD80
and CD83 expression.  Bortozomib caused a down-regulation of all  analysed surface
molecules except CD14 and osteoactivin. In immature imMoDC, carfilzomib caused a
statistically  significant  up-regulation  of  CD80,  bortezomib  caused  a  statistically
significant up-regulation of CD83. This suggests carfilzomib having little effect on the
phenotype  of  immature  as  well  as  LPS  matured  mMoDC.  Migratory  function  was
measured by cell migration through a porous membrane. Carfilzomib, as opposed to
bortezomib,  did  not  significantly  reduce  in  vitro migratory  function  of  mMoDC.
Cytokine secretion was analysed in ELISA assays of cell-deprived cell culture fluid.
Carfilzomib appears to affect mMoDC cytokine production less than bortezomib which
caused a statistically significant decrease in imMoDC MCP-1/CCL2 concentration and
mMoDC MIP-1α/CCL3 concentration while non-significant results showed a consistent
trend of a more pronounced decrease in cytokine concentration in bortezomib than in
carfilzomib.  Our  results  suggest  carfilzomib  only  having  minor  effects  on  MoDC
phenotype and function and it therefore being better suited for combination with tumour
vaccination. However, more functional analyses will be needed to support this claim.
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7. German Summary
Dendritische Zellen (DC) sind die potentesten antigenpräsentierenden Zellen und somit
wichtige  Vermittler  der  Kommunikation  von  angeborenem  und  adaptivem
Immunsystem. Grund hierfür ist u. a.  die einzigartige Fähigkeit,  aufgenommene und
prozessierte Antigene auf MHC I und MHC II zu präsentieren und die Fähigkeit, naive
CD8+ T-Zellen mit kostimulatorischen Oberflächenrezeptoren zu primen. Carfilzomib
ist ein Proteasominhibitor der zweiten Generation und für die Therapie des multiplen
Myeloms zugelassen, welches in den meisten Fällen nicht heilbar ist. Diese Arbeit sollte
den Effekt von Carfilzomib auf in vitro aus Monozyten generierten dendritischen Zellen
(MoDC),  welche  in  einigen  Tumor-Impfungen  Anwendung  finden,  analysieren.  Der
MoDC-Phänotyp wurde  durch  Färben  mit  fluoreszenzmarkierten  Antikörpern  gegen
verschiedene  Oberflächenmoleküle  und  anschließende  Messung  am
Durchflusszytometer  bestimmt.  Bei  reifen  MoDC  verursachte  Carfilzomib  eine
statistisch signifikante,  weniger als  bei Bortezomib ausgeprägte Herabregulation von
CD80 und CD83. Bortezomib verursachte bei reifen MoDC eine Herabregulation aller
Oberflächenmoleküle außer CD14 und Osteoaktivin. Bei unreifen MoDC verursachte
Carfilzomib eine statistisch signifikante Hochregulation von CD80 und Bortezomib eine
statistisch signifikante Hochregulation von CD83. Dies legt nahe, dass Carfilzomib den
Phänotyp  nur  geringfügig  verändert.  Die Zellmigration  durch  eine  poröse  Membran
zeigte keine signifikante Verschlechterung. Die Zytokinsekretion wurde durch ELISAs
aus  zellfreier  Zellkulturflüssigkeit  bestimmt.  In  der  Bortezomib  Gruppe  wurde  bei
unreifen  MoDC  eine  signifikant  geringere  Durchschnittskonzentration  von
MCP-1/CCL2,  bei  reifen  MoDC  eine  signifikant  geringere  MIP-1α/CCL3
Konzentration  gemessen.  Bei  allen  anderen  Zytokinen  zeigte  sich  als  Trend,  dass
Bortezomib  einen  ausgeprägteren  Zytokinkonzentrationsabfall  verursachte  als
Carfilzomib. Diese Ergebnisse suggerieren, dass Carfilzomib sich zur therapeutischen
Kombination mit Tumorvakzinen besser eignet als sein Vorgänger Bortezomib.
68
8. References
1.  Aderem A. Phagocytosis  and the Inflammatory Response.  J  Infect  Dis.  2003 Jun
15;187(s2):S340–5. 
2. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive
protein. Immunopharmacology. 1999 May;42(1–3):23–30. 
3. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions
of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007 Jul;7(7):543–55. 
4.  Gelman  JS,  Sironi  J,  Berezniuk  I,  Dasgupta  S,  Castro  LM,  Gozzo  FC,  et  al.
Alterations  of  the  Intracellular  Peptidome  in  Response  to  the  Proteasome  Inhibitor
Bortezomib. Gartel AL, editor. PLoS ONE. 2013 Jan 7;8(1):e53263. 
5. Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior
antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells
as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010 Jun 7;207(6):1273–81.
6.  Poulin  LF,  Salio  M, Griessinger  E,  Anjos-Afonso F,  Craciun L,  Chen J-L,  et  al.
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of
mouse CD8alpha+ dendritic cells. J Exp Med. 2010 Jun 7;207(6):1261–71. 
7. Schroder K, Hertzog PJ, Ravasi T,  Hume DA. Interferon-gamma: an overview of
signals, mechanisms and functions. J Leukoc Biol. 2004 Feb;75(2):163–89. 
8.  Slavik  JM,  Hutchcroft  JE,  Bierer  BE.  CD28/CTLA-4  and  CD80/CD86 families:
signaling and function. Immunol Res. 1999;19(1):1–24. 
9. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–63. 
10.  Crotty  S.  A brief  history  of  T  cell  help  to  B  cells.  Nat  Rev  Immunol.  2015
Mar;15(3):185–9. 
11. Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R. Cell
death  mechanisms  induced  by  cytotoxic  lymphocytes.  Cell  Mol  Immunol.  2009
Feb;6(1):15–25. 
12.  Paulsen  M,  Janssen  O.  Pro-  and anti-apoptotic  CD95 signaling  in  T cells.  Cell
Commun Signal CCS. 2011 Apr 8;9:7. 
13. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid
organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973 May
1;137(5):1142–62. 
14. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature.
1998 Mar 19;392(6673):245–52. 
15. Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, et al.
CD83 expression  on  dendritic  cells  and  T cells:  correlation  with  effective  immune
responses. Eur J Immunol. 2007 Mar;37(3):686–95. 
16.  Banchereau  J,  Briere  F,  Caux  C,  Davoust  J,  Lebecque  S,  Liu  YJ,  et  al.
Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811. 
17. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, et
al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells
loaded with killed allogeneic melanoma cells. J Exp Med. 2000 Dec 4;192(11):1535–
44. 
69
18. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells,
expanded  with  dendritic  cells  presenting  a  single  autoantigenic  peptide,  suppress
autoimmune diabetes. J Exp Med. 2004 Jun 7;199(11):1467–77. 
19. McKenna K, Beignon A-S, Bhardwaj N. Plasmacytoid dendritic cells: linking innate
and adaptive immunity. J Virol. 2005 Jan;79(1):17–27. 
20.  Gabrilovich  D.  Mechanisms  and  functional  significance  of  tumour-induced
dendritic-cell defects. Nat Rev Immunol. 2004 Dec;4(12):941–52. 
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70. 
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar
4;144(5):646–74. 
23. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion
in  cancer:  Mechanistic  basis  and  therapeutic  strategies.  Semin  Cancer  Biol.  2015
Dec;35 Suppl:S185–98. 
24. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses
through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol Baltim
Md 1950. 1996 Jan 1;156(1):73–8. 
25.  Palucka  K,  Banchereau  J.  Cancer  immunotherapy  via  dendritic  cells.  Nat  Rev
Cancer. 2012 Mar 22;12(4):265–77. 
26. Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, et al. Limited
Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in
Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified
Peptides. Clin Cancer Res. 2012 Dec 1;18(23):6485–96. 
27. Leffers N, Lambeck AJA, Gooden MJM, Hoogeboom B-N, Wolf R, Hamming IE, et
al.  Immunization  with  a  P53  synthetic  long  peptide  vaccine  induces  P53-specific
immune responses in ovarian cancer patients, a phase II trial. Int J Cancer. 2009 Nov
1;125(9):2104–13. 
28. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et  al.
Multipeptide  immune  response  to  cancer  vaccine  IMA901  after  single-dose
cyclophosphamide  associates  with  longer  patient  survival.  Nat  Med.  2012
Aug;18(8):1254-61. 
29. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines
for cancer. Nat Rev Immunol. 2018 Mar;18(3):168–82. 
30. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of
immune  responses  in  patients  with  B-cell  lymphoma  against  the  surface-
immunoglobulin  idiotype  expressed  by  their  tumors.  N  Engl  J  Med.  1992  Oct
22;327(17):1209–15. 
31. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al.
Vaccination  with  patient-specific  tumor-derived  antigen  in  first  remission  improves
disease-free survival in follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol.
2011 Jul 10;29(20):2787–94. 
32.  Fritsch  EF,  Rajasagi  M,  Ott  PA,  Brusic  V,  Hacohen  N,  Wu  CJ.  HLA-binding
properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun;2(6):522–9.
33. Yarchoan M, Johnson BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens
to augment antitumour immunity. Nat Rev Cancer. 2017;17(4):209–22. 
70
34.  Dubensky TW, Reed SG. Adjuvants for cancer  vaccines.  Semin Immunol.  2010
Jun;22(3):155–61. 
35.  Coffman RL, Sher  A, Seder RA. Vaccine adjuvants:  putting innate  immunity to
work. Immunity. 2010 Oct 29;33(4):492–503. 
36.  Santos  PM, Butterfield  LH. Dendritic  Cell–Based Cancer  Vaccines.  J  Immunol.
2018 Jan 15;200(2):443–9. 
37. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, et al. Vaccination
with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune
responses in patients with multiple myeloma. Blood. 2011 Jan 13;117(2):393–402. 
38. Jung S-H, Lee H-J, Lee Y-K, Yang D-H, Kim H-J, Rhee JH, et al. A phase I clinical
study  of  autologous  dendritic  cell  therapy  in  patients  with  relapsed  or  refractory
multiple myeloma. Oncotarget. 2017 Jun 20;8(25):41538–48. 
39.  Lacy  MQ,  Mandrekar  S,  Dispenzieri  A,  Hayman  S,  Kumar  S,  Buadi  F,  et  al.
Idiotype-pulsed  antigen-presenting  cells  following  autologous  transplantation  for
multiple myeloma may be associated with prolonged survival.  Am J Hematol.  2009
Dec;84(12):799–802. 
40. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, et al. Vaccination with
dendritic  cell/tumor  fusions  following  autologous  stem  cell  transplant  induces
immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res Off
J Am Assoc Cancer Res. 2013 Jul 1;19(13):3640–8. 
41. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J-P, Johnston DA, et
al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective
clinical  responses  and  MART-1  specific  CD8+  T-cell  immunity.  J  Immunother
Hagerstown Md 1997. 2006 Oct;29(5):545–57. 
42.  Kantoff  PW,  Higano  CS,  Shore  ND,  Berger  ER,  Small  EJ,  Penson  DF,  et  al.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med.
2010 Jul 29;363(5):411–22. 
43. Li D, Romain G, Flamar A-L, Duluc D, Dullaers M, Li X-H, et al. Targeting self-
and  foreign  antigens  to  dendritic  cells  via  DC-ASGPR  generates  IL-10-producing
suppressive CD4+ T cells. J Exp Med. 2012 Jan 16;209(1):109–21. 
44. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes
multiple myeloma: a prospective study. Blood. 2009 May 28;113(22):5412–7. 
45. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et
al.  Revised  International  Staging  System  for  Multiple  Myeloma:  A  Report  From
International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863–9. 
46. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015
Feb;65(1):5–29. 
47. Cancer Stat Facts: Myeloma [Internet]. [cited 2018 Mar 21]: https://seer.cancer.gov/
statfacts/html/mulmy.html
48.  Attal  M,  Harousseau  JL,  Stoppa  AM,  Sotto  JJ,  Fuzibet  JG,  Rossi  JF,  et  al.  A
prospective,  randomized  trial  of  autologous  bone  marrow  transplantation  and
chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med.
1996 Jul 11;335(2):91–7. 
71
49. Roehnisch T, Then C, Nagel W, Blumenthal C, Braciak T, Donzeau M, et al. Phage
idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. J
Transl Med. 2014 May 9;12:119. 
50.  FDA  Approval  for  Bortezomib  [Internet].  [cited  2018  Mar  21]:
https://www.cancer.gov/about-cancer/treatment/drugs/fda-bortezomib
51. Bonvini  P,  Zorzi E,  Basso G, Rosolen A. Bortezomib-mediated 26S proteasome
inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell
lymphoma. Leukemia. 2007 Apr;21(4):838–42. 
52. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed
multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011
May;12(5):431–40. 
53. Jagannath S, Durie BGM, Wolf JL, Camacho ES, Irwin D, Lutzky J, et al. Extended
follow-up  of  a  phase  2  trial  of  bortezomib  alone  and  in  combination  with
dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009
Sep;146(6):619–26. 
54.  Fu  W,  Delasalle  K,  Wang  J,  Song  S,  Hou  J,  Alexanian  R,  et  al.  Bortezomib-
cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol.
2012 Dec;35(6):562–5. 
55.  FDA  Approval  for  Carfilzomib  [Internet].  [cited  2018  Mar  21]:
https://www.cancer.gov/about-cancer/treatment/drugs/fda-carfilzomib
56. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2
study  of  single-agent  carfilzomib  (PX-171-003-A1)  in  patients  with  relapsed  and
refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817–25. 
57. Carfilzomib (Code C52196) NCIthesaurus. In [cited 2018 Mar 21]. Available from:
https://ncit.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?
dictionary=NCI_Thesaurus&version=16.04d&code=C52196&ns=NCI_Thesaurus&typ
e=properties&key=null&b=1&n=0&vse=null
58. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al.  Potent
activity  of  carfilzomib,  a  novel,  irreversible  inhibitor  of  the  ubiquitin-proteasome
pathway,  against  preclinical  models  of  multiple  myeloma.  Blood.  2007  Nov
1;110(9):3281–90. 
59.  Muchtar E,  Gertz MA, Magen H. A practical review on carfilzomib in multiple
myeloma. Eur J Haematol. 2016 Jun;96(6):564–77. 
60. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I,  Oriol A, et al.
Carfilzomib,  Lenalidomide,  and Dexamethasone for  Relapsed Multiple  Myeloma.  N
Engl J Med. 2015 Jan 8;372(2):142–52. 
61.  Dimopoulos  MA,  Moreau  P,  Palumbo  A,  Joshua  D,  Pour  L,  Hájek  R,  et  al.
Carfilzomib  and  dexamethasone  versus  bortezomib  and  dexamethasone  for  patients
with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3,
open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27–38. 
62. Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation
for multiple myeloma. Semin Hematol. 2001 Jul;38(3):243–9. 
72
63. Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, et al.
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either
up- or down-regulate antigen presentation at  nontoxic doses.  J  Immunol Baltim Md
1950. 2000 Jun 15;164(12):6147–57. 
64. Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, Rocco I, et al.
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur
J Immunol. 2006 Mar;36(3):681–9. 
65. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grünebach
F,  et  al.  Proteasome  inhibitor  bortezomib  modulates  TLR4-induced  dendritic  cell
activation. Blood. 2006 Jul 15;108(2):551–8. 
66. Leone P, Berardi S, Frassanito MA, Ria R, De Re V, Cicco S, et al. Dendritic cells
accumulate in the bone marrow of myeloma patients where they protect tumor plasma
cells from CD8+ T-cell killing. Blood. 2015 Sep 17;126(12):1443–51. 
67. Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, et al. The
antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-
cell-based immunotherapy. Blood. 2015 Sep 3;126(10):1203–13. 
68. Kowalewski DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, et al.
Carfilzomib  alters  the  HLA-presented  peptidome  of  myeloma  cells  and  impairs
presentation of peptides with aromatic C-termini. Blood Cancer J. 2016 Apr;6(4):e411–
e411. 
69. Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, et al. Generation of
mature dendritic cells from human blood. An improved method with special regard to
clinical applicability. J Immunol Methods. 1996 Sep 27;196(2):137–51. 
70. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured
human  dendritic  cells  is  maintained  by  granulocyte/macrophage  colony-stimulating
factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med.
1994 Apr 1;179(4):1109–18. 
71.  Caux  C,  Massacrier  C,  Vanbervliet  B,  Barthelemy  C,  Liu  YJ,  Banchereau  J.
Interleukin  10  inhibits  T  cell  alloreaction  induced  by  human  dendritic  cells.  Int
Immunol. 1994 Aug;6(8):1177–85. 
72. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of
autocrine  IL-10 on dendritic  cell  functions.  J  Immunol  Baltim Md 1950.  2001 Apr
1;166(7):4312–8. 
73. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor
activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007
Jul 1;67(13):6383–91. 
74.  Wang  Z,  Yang  J,  Kirk  C,  Fang  Y,  Alsina  M,  Badros  A,  et  al.  Clinical
Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib. Drug Metab
Dispos. 2013 Jan 1;41(1):230–7. 
75. Castiello L, Sabatino M, Jin P, Clayberger C, Marincola FM, Krensky AM, et al.
Monocyte-derived  DC maturation  strategies  and  related  pathways:  a  transcriptional
view. Cancer Immunol Immunother. 2011 Apr;60(4):457–66. 
73
76. Vermes I,  Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for
apoptosis.  Flow  cytometric  detection  of  phosphatidylserine  expression  on  early
apoptotic  cells  using fluorescein labelled Annexin V.  J  Immunol Methods.  1995 Jul
17;184(1):39–51. 
77. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple
method  for  measuring  thymocyte  apoptosis  by  propidium  iodide  staining  and  flow
cytometry. J Immunol Methods. 1991 Jun 3;139(2):271–9. 
78. Knödler A, Schmidt SM, Bringmann A, Weck MM, Brauer KM, Holderried T a. W,
et  al.  Post-transcriptional  regulation  of  adapter  molecules  by  IL-10  inhibits  TLR-
mediated activation of antigen-presenting cells. Leukemia. 2009 Mar;23(3):535–44. 
79. Cernadas M, Lu J, Watts G, Brenner MB. CD1a expression defines an interleukin-
12  producing  population  of  human  dendritic  cells.  Clin  Exp  Immunol.  2009
Mar;155(3):523-33. 
80. van Kooyk Y, Geijtenbeek TBH. DC-SIGN: escape mechanism for pathogens. Nat
Rev Immunol. 2003 Sep;3(9):697–709. 
81.  Ohl  L,  Mohaupt  M, Czeloth  N,  Hintzen  G,  Kiafard  Z,  Zwirner  J,  et  al.  CCR7
governs skin dendritic cell migration under inflammatory and steady-state conditions.
Immunity. 2004 Aug;21(2):279–88. 
82. Schwarzbich M-A, Gutknecht M, Salih J, Salih HR, Brossart P, Rittig SM, et al. The
immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic
cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother CII. 2012
Feb;61(2):193–202. 
83. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML. Human dendritic cells require
exogenous interleukin-12-inducing factors to direct the development of naive T-helper
cells toward the Th1 phenotype. Blood. 1997 Sep 1;90(5):1920–6. 
84. Dudek AM, Martin S, Garg AD, Agostinis P. Immature, Semi-Mature, and Fully
Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer
Immunity. Front Immunol. 2013 Dec 11;4:438. 
85.  Gonzalez-Quesada  C,  Frangogiannis  NG.  Monocyte  chemoattractant
protein-1/CCL2 as a biomarker in  acute coronary syndromes.  Curr Atheroscler Rep.
2009 Mar;11(2):131–8. 
86.  Ajuebor  MN,  Kunkel  SL,  Hogaboam  CM.  The  role  of  CCL3/macrophage
inflammatory  protein-1alpha  in  experimental  colitis.  Eur  J  Pharmacol.  2004  Aug
30;497(3):343–9. 
87.  Suffee N, Richard B, Hlawaty H, Oudar O, Charnaux N, Sutton A. Angiogenic
properties  of  the  chemokine  RANTES/CCL5.  Biochem  Soc  Trans.  2011
Dec;39(6):1649-53. 
88. Jones SA. Directing transition from innate to acquired immunity: defining a role for
IL-6. J Immunol Baltim Md 1950. 2005 Sep 15;175(6):3463–8. 
89. Vignali  DAA, Kuchroo VK. IL-12 family cytokines: immunological playmakers.
Nat Immunol. 2012 Jul 19;13(8):722–8. 
90. Straube C, Wehner R, Wendisch M, Bornhäuser M, Bachmann M, Rieber EP, et al.
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid
blood dendritic cells. Leukemia. 2007 Jul;21(7):1464–71. 
74
91.  Chang  C-L,  Hsu  Y-T,  Wu  C-C,  Yang  Y-C,  Wang  C,  Wu  T-C,  et  al.  Immune
Mechanism of the Antitumor Effects Generated by Bortezomib. J Immunol. 2012 Sep
15;189(6):3209-20. 
92.  Zinser  E,  Rössner  S,  Littmann L,  Lüftenegger  D,  Schubert  U,  Steinkasserer  A.
Inhibition of the proteasome influences murine and human dendritic cell development in
vitro and in vivo. Immunobiology. 2009;214(9–10):843–51. 
93. Wang Y, Liang Y, Zhang Y, Wu D, Liu H. Bortezomib inhibits bone marrow-derived
dendritic cells. Int J Clin Exp Pathol. 2015;8(5):4857–62. 
94. Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging
therapies  for  acute  and  chronic  graft  versus  host  disease.  Ther  Adv Hematol.  2018
Jan;9(1):21–46. 
95.  Dall’Era  M,  Davis  J.  CTLA4Ig:  a  novel  inhibitor  of  costimulation.  Lupus.
2004;13(5):372–6. 
96. NCT03457142 [Internet]: https://clinicaltrials.gov/ct2/show/NCT03457142
97. Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D, et al. CD28-
mediated  pro-survival  signaling  induces  chemotherapeutic  resistance  in  multiple
myeloma. Blood. 2014 Jun 12;123(24):3770–9. 
98. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, et al. In Vitro and In Vivo
Therapeutic  Efficacy  of  Carfilzomib  in  Mantle  Cell  Lymphoma:  Targeting  the
Immunoproteasome. Mol Cancer Ther. 2013 Nov 1;12(11):2494–504. 
99.  Busonero  C,  Leone  S,  Klemm  C,  Acconcia  F.  A functional  drug  re-purposing
screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and
cell proliferation in breast cancer cells. Mol Cell Endocrinol. 2018 Jan 15;460:229–37. 
100. Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman JP. Proteasome
inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death
in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017
Sep 22;8(42):72281–301. 
101. Shi Y, Yu Y, Wang Z, Wang H, Bieerkehazhi S, Zhao Y, et al. Second-generation
proteasome  inhibitor  carfilzomib  enhances  doxorubicin-induced  cytotoxicity  and
apoptosis in breast cancer cells. Oncotarget. 2016 08;7(45):73697–710. 
102. Mehta A, Zhang L, Boufraqech M, Zhang Y, Patel D, Shen M, et al. Carfilzomib is
an effective anticancer agent in anaplastic thyroid cancer. Endocr Relat Cancer. 2015
Jun;22(3):319–29. 
103. Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL. Carfilzomib
demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung
cancer models. J Exp Clin Cancer Res CR. 2014 Dec 31;33:111. 
104.  Forsythe  N,  Refaat  A,  Javadi  A,  Khawaja  H,  Weir  J-A,  Emam H,  et  al.  The
unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant
colorectal cancer. Mol Cancer Ther. 2018 Feb 26;molcanther.0603.2017. 
105.  Ao  L,  Reichel  D,  Hu  D,  Jeong  H,  Kim  KB,  Bae  Y,  et  al.  Polymer  micelle
formulations of proteasome inhibitor carfilzomib for improved metabolic stability and
anticancer efficacy in human multiple myeloma and lung cancer cell lines. J Pharmacol
Exp Ther. 2015 Nov;355(2):168–73. 
75
106. Zhang L, Yang X, Sun Z, Li J,  Zhu H, Li J,  et  al.  Dendritic cell  vaccine and
cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung
cancer. Oncol Lett. 2016 Apr;11(4):2605–10. 
107. Lee H-M, Lee E, Yeo S-Y, Shin S, Park H-K, Nam D-H, et al. Drug repurposing
screening identifies bortezomib and panobinostat as drugs targeting cancer associated
fibroblasts (CAFs) by synergistic induction of apoptosis. Invest New Drugs [Internet].
2018 Jan 18 [cited 2018 Mar 29]: http://link.springer.com/10.1007/s10637-017-0547-8
76
9. List of Tables
Table 2.1: Devices
Table 2.2: Expendable Materials
Table 2.3.1: Buffers, Solutions, Chemicals
Table 2.3.2: Media and Additives
Table 2.3.3: Fluorescent Antibodies for Flow Cytometry
Table 2.3.4: Cytokines
Table 2.4: Miscellaneous
Table 3.1.4: Trial Set-up
Table 3.2.1: FACS Antibodies – Target and Colour
Table 3.3: Measured Cytokines and Their Functions
77
10. List of Figures
Fig. 1.1.3: Modified from “The Antigen-presentation Pathways in Dendritic Cells”
Fig. 1.1.5: Modified from “Outline of normal DC differentiation and the role of  
DC in antitumour immunity”
Fig. 1.1.7 a: Modified from “Manipulating the immune response to tumours.”
Fig. 1.1.7 b: Modified from “The state of the art in translating DC vaccines to the  
clinic”
Fig. 4.1.1 a: Cell Viability MoDC, 300 nM Carfilzomib
Fig. 4.1.1 b: Cell Viability MoDC, 100 nM Carfilzomib
Fig. 4.1.2a: Cell Viability U266, Carfilzomib
Fig. 4.1.2b: Cell Viability U266, Bortezomib
Fig. 4.2: Normal Phenotype of Untreated imMoDC and mMoDC
Fig. 4.2.1 a: CD14 Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.1 b: CD14 Expression in imMoDC
Fig. 4.2.1 c: CD14 Expression in mMoDC 
Fig. 4.2.2 a: CD1a Expression in imMoDC
Fig. 4.2.2 b: CD1a Expression in mMoDC
Fig. 4.2.2 c: CD1a Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.3 a: DC-SIGN Expression in imMoDC  
Fig. 4.2.3 b: DC-SIGN Expression in mMoDC 
Fig. 4.2.3 c: DC-SIGN Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.4 a: CD83 Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.4 b: CD83 Expression in mMoDC 
Fig. 4.2.4 c: CD83 Expression in imMoDC 
Fig. 4.2.5 a: CD80 Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.5 b: CD80 Expression imMoDC
Fig. 4.2.5 c: CD80 Expression in mMoDC
Fig. 4.2.6 a: CD86 Expression in imMoDC 
Fig. 4.2.6 b: CD86 Expression in mMoDC
78
Fig. 4.2.6 c: CD86 Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.7 a: HLA-DR Expression in imMoDC 
Fig. 4.2.7 b: HLA-DR Expression in mMoDC
Fig. 4.2.7 c: HLA-DR Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.8 a: CCR7 Expression in imMoDC
Fig. 4.2.8 b: CCR7 Expression in mMoDC
Fig. 4.2.8 c: CCR7 Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.2.9 a: Osteoactivin Expression in imMoDC
Fig. 4.2.9 b: Osteoactivin Expression in mMoDC
Fig. 4.2.9 c: Osteoactivin Expression in imMoDC and mMoDC, Exemplary Overlay
Fig. 4.3 a: Migration imMoDC
Fig. 4.3 b: Migration mMoDC
Fig. 4.4.1 a: MIP-1α/CCL3 ELISA, imMoDC
Fig. 4.4.1 b: MIP-1α/CCL3 ELISA, mMoDC
Fig. 4.4.2 a: MCP-1/CCL2  ELISA, imMoDC
Fig. 4.4.2 b: MCP-1/CCL2 ELISA, mMoDC
Fig. 4.4.3 a: Rantes/CCL5 ELISA, imMoDC
Fig. 4.4.3 b: Rantes/CCL5 ELISA, mMoDC
Fig. 4.4.4 a: IL-6 ELISA, imMoDC
Fig. 4.4.4 b: IL-6 ELISA, mMoDC
Fig. 4.4.5 a: IL-12 ELISA, imMoDC
Fig. 4.4.5 b: IL-12 ELISA, mMoDC
79
11. List of Abbreviations
ASGPR Asialoglycoprotein Receptor
APC Antigen-prensenting Cell / Allophycocyanin (FACS)
BSA Bovine Serum Albumin
CCL Chemokine Ligand
CCR Chemokine Receptor
CD  Cluster(s) of Differentiation
CD40L  CD40 Ligand
CTL Cytotoxic T Lymphocyte(s)
DC  Dendritic Cell
i/mDC  Immature/Mature Dendritic Cell(s)
MoDC  Monocyte-Derived Dendritic Cell(s)
imMoDC Immature Monocyte-Derived Dendritic Cell(s)
mMoDC Mature Monocyte-Derived Dendritic Cell(s)
DMSO  Dimethylsulfoxid
DNA  Desoxyribonucleic Acid
FACS  Fluorescence-Activated Cell Sorter
FCS  Fetal Calf Serum
FDA Food and Drug Administration
FITC Fluorescein Isothiocyanate
FSC Forward Scatter
GM-CSF  Granulocyte-Macrophage-Colony Stimulating Factor
HER2 Human Epidermal Growth Factor 2
HLA-DR Human Leukocyte Antigen-Antigen D Related
HPC Hematopoietic Progenitor Cells
Ig Immunoglobulin
IL Interleukin
iMC Immature Myeloid Cell
LDL Low-Densitiy Lipoprotein
80
LDH Lactate Dehydrogenase
LPS  Lipopolysaccharid
MGUS Monoclonal Gammopathy of Undetermined Significance
MHC I / II  Major Histocompability Complex I / II
MAP Mitogen Activated Protein
MCP Monocyte Chemotactic Protein
MIP Macrophage Inflammatory Protein
MYD88 Myeloid Differentiation Primary Response 88
NF Nuclear Factor
PAMP Pathogen-associated Molecular Pattern
PBMC Peripheral Blood Mononuclear Cell
PBS  Phosphate Buffered Saline
PE  Phycoerythrin
PerCP Peridinin-Chlorophyll-Protein Complex
PI3-K  Phosphatidyl-Inositol-3-Kinase
PRR  Pattern Recognation Receptor
PSA Prostate Specific Antigen
RANTES Regulated on Activation, Normal T Cell Expressed and Secreted 
RNA Ribonucleic Acid
SSC  Side Scatter
TCR  T Cell Receptor
Tf h Cell T Follicular Helper Cell
Th Cell T Helper Cell
Treg Cell Regulatory T Cell
TGF Transforming Growth Factor
TLR  Toll-Like Receptor 
TLR-L  Toll-Like Receptor Ligand
TNF  Tumour Necrosis Factor
81
12. Erklärung zum Eigenanteil der Dissertationsschrift 
Die Arbeit wurde in der medizinischen Universitätsklinik Tübingen, AG Experimentelle
Immuntherapie unter Betreuung von PD Dr. rer. nat. Frank Grünebach durchgeführt. 
Die Konzeption der Studie erfolgte durch Dr. med. Susanne M. Rittig, Dr. med. Daniela
Dörfel und Dr. rer. nat. Frank Grünebach. 
Die  ELISA  und  Annexin-V-Fluoscein  /  PI  Methode  wurde  durch  Sylvia  Klein
durchgeführt. Die anderen Versuche wurden nach Einarbeitung durch Sylvia Klein von
mir eigenständig  durchgeführt. 
Die statistische Auswertung erfolgte eigenständig durch mich. 
Die Betreuung der Arbeit erfolgte durch Dr. med. Susanne M. Rittig, Dr. med. Daniela
Dörfel und Dr. rer. nat. Frank Grünebach. Die Korrektur der Arbeit erfolgte durch Dr.
med. Susanne Rittig und PD Dr. rer. nat. Frank Grünebach.
Ich versichere, das Manuskript selbständig verfasst zu haben und keine weiteren als die
von mir angegebenen Quellen verwendet zu haben. 
Hamm, den 21.06.2019
Marius Dahlfrancis
82
13. Danksagung
Zuerst möchte ich meinem Doktorvater PD Dr. rer. nat. Frank Grünebach dafür danken,
dass er mir diese Doktorarbeit unter seiner Führung ermöglicht hat. 
Auch bedanke ich mich bei Dr. med. Susanne Rittig und Dr. med. Daniela Dörfel für die
persönliche Betreuung während des Projekts.
Besonderer  Dank  gilt  auch  Frau  Sylvia  Klein,  die  trotz  Verpflichtungen  in  der
universitären  Kinderklinik  viel  Zeit  und  Geduld  für  meine  Einarbeitung  aufbrachte.
Ohne ihre Mithilfe wäre diese Arbeit nicht möglich gewesen.
Ich  möchte  mich  bei  allen  Mitarbeitern  im  Labor,  sowohl  für  das  angenehme
Arbeitsklima und die kleinen Ratschläge mit großer Wirkung bedanken, als auch für die
nette Zeit außerhalb des Labors und auf der DGHO Tagung in Basel.
Meiner Mutter danke ich für ihre jahrzehntelangen Bemühungen, meine Arbeitseffizienz
von zu langsam auf adäquat zu steigern und natürlich für ihre moralische Unterstützung
während meiner gesamten Ausbildung. 
Meiner  Taufpatin  Margret  Juchmann  möchte  ich  ebenfalls  für  die  moralische
Unterstützung und die stets ermutigenden Worte danken.
Meinem Bruder danke ich von ganzem Herzen für das professionelle Korrekturlesen
und nützliche Tipps wie z. B. den Speed Reader.
Zuletzt danke ich natürlich auch allen lieben Menschen aus meinem Freundeskreis, die
ein  wichtiges  Gegengewicht  zu  den  Stressoren  des  Projekts  und  anderen
Verpflichtungen schafften und schaffen. 
83
